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CHAPTER ONE
INTRODUCTION
According to the World Health Organization (WHO) each year 8.2 million people
die worldwide from cancer (World Health Organization, 2016). In the United States
cancer is the second leading cause of death, and the American Cancer Society (ACS)
estimates that one in two men and one in three women living in the U.S. will develop
cancer at some point in their lives (American Cancer Society, 2016). Due to the
prevalence of cancer there are countless institutions and scientist researching cures,
treatments, and other areas of aid. The ACS has invested over $4 billion in research since
1946 (American Cancer Society, 2016). The National Cancer Institute, the U.S.
government’s primary agency for cancer related research, funded 3,100 institutions and
over 14,000 investigators in 2014 (National Cancer Institute, 2016). Their efforts have
assisted in lowering the death rate of cancer by 22% from 1990-2011 (National Cancer
Institute, 2016). Although annual death rates are consistently decreasing, the projected
number of new cases of cancer will increase by 70% over the next 20 years.
There are several options available for the treatment and management of cancer,
some of which are: chemotherapy, radiation therapy, surgery, angiogenesis inhibitor
therapy, and photodynamic therapy. Chemotherapy is the most popular course of
treatment. Chemotherapy uses drugs to stop or slow the growth of cancer cells. It is often
combined with radiation therapy of surgery. A major drawback of chemotherapy is its
1
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robustness. It attacks both cancerous and healthy cells which leads to many unwanted
side effects.
Radiation therapy damages cancer cells’ DNA by using X-rays, gamma rays, or
other charged particles. This method of treatment can damage healthy cells as well.
Surgery is commonly coupled with radiation therapy to remove the tumor and some of
the tissues around it, but there is high incidence of reoccurrence.
Angiogenesis inhibitor therapy prevents the formation of new blood vessels which
in return prevents tumors from growing. This type of treatment does not “cure” the
patient it only halts the tumors growth. To rid the patient of the cancer this therapy is
combined with radiation and/or chemotherapy, leading to aforementioned unwanted side
effects.
Photodynamic therapy (PDT) use light for the treatment of cancer (Figure 1). A
light sensitive drug is given to a patient and absorbed by cells throughout the body. After
a period of time most of the drug leaves the body, but the cancer cells retain the drug. The
cells laden with the drug is exposed to light and the drug becomes toxic to cells
destroying the cancer. One limitation of this method is the light needed to activate most
drugs cannot pass through more than one centimeter of tissue (Vrouenraets, et al., 2003)
therefore this restricts the types and sizes of cancer treated. Also, the drug is absorbed by
cells throughout the body and can be retained by non-cancerous cells which leads to
unwanted cell death and prolonged light sensitivity throughout the entire body. For
these reasons, our research focuses on the development of new PDT agents to increase
specificity and to widen the scope of its use.

3

Figure 1. Photodynamic Therapy Schematic. A photosensitizer is given to the patient
either topically or intravenously. Cancerous tumors preferentially retain the
photosensitizer while healthy cells do not. The tumor is then irradiated with light at the
appropriate wavelength which in turns activates the photosensitizer to become cytotoxic
to the tumor. (Mroz, et al., 2011)
Historical Perspective on Photodynamic Therapy
The use of phototherapy can be traced back to Ancient Egypt, Indian, and Chinese
civilizations. In 1900 Oscar Raab observed that acridines (Table 1) in the presence of
daylight are lethal to protozoan paramecium (Pervaiz and Malini, 2006). Raab along with
his mentor, Herman Von Tappeiner, coined the term “photodynamic reaction” to
differentiate their dynamic photobiological reactions that occurred in the presence of
molecular oxygen from the photosensitization of photographic plates by certain
chromophores (Pervaiz and Malini, 2006). In 1901 Niels Finsen discovered that red light
can be used in the prevention of the formation and discharge of small pox pustules. He
also discovered that ultraviolet light can be used to treat cutaneous tuberculosis (Dolman,
et al., 2003). He was awarded him the Nobel Prize in 1903 for this research (Dolman, et
al., 2003). In 1903 Tappeiner and Jodlbauer treated skin tumors with topically applied
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eosin (Table 1) and white light (Dolman, et al., 2003). This was the beginning of modern
PDT.
Modern PDT began with the study of porphyrins as photosensitizers. In 1911
Hausmann studied hematoporphyrins (Table 1) to determine their photosensitivity and
phototoxic effects (Pervaiz and Malini, 2006). In 1955 hematoporphyrin derivatives
(HPD) were developed by Samuel Schwartz (Pervaiz and Malini, 2006). These
derivatives were more phototoxic than hematoporphyrins (Pervaiz and Malini, 2006).
Five years later Richard Lipson and Edward Baldes at the Mayo Clinic showed that
Schwartz’ HPD localized to tumors and emitted fluorescence which could be used to
detect tumors (Pervaiz and Malini, 2006). Thomas Dougherty reported in 1975 that HPD
and red light destroyed mammary tumor growth in mice and J.F. Kelly used HPD and
light to kill bladder carcinoma in mice (Pervaiz and Malini, 2006). The first PDT drug
was approved by the Federal Drug Administration (F.D.A.) in the U.S. in 1993.

Acridine

Eosin

Hematoporphyrin

Table 1. Early Photosensitizers: Acridine and Eosin were observed in 1900 and 1903
respectively to be lethal in the presence of light. Hematoporphryins were used in 1911.
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Photodynamic Therapy Mechanism
PDT has three requirements: a photosensitizer (PS), light at an appropriate
wavelength, and molecular oxygen. A PS is a molecule that upon activation by light at a
particular wavelength in the presence of molecular oxygen produces reactive oxygen
species (ROS). The PS absorbs photons from light and this energy promotes one electron
from the singlet state to a high energy orbital but it retains its spin. This state is short
lived and is relaxed by fluorescence or internal conversion to heat (Robertson, 2009).
This excited state may also undergo intersystem crossing in which the spin of the excited
electrons inverts and forms an excited triplet state. This triplet state is long lived and can
proceed via two routes, Type I reactions and Type II reactions (Figure 2) (Robertson,
2009). In Type I reactions the PS in the triplet state reacts directly with a substrate. The
PS tranfers a proton and/or electron to the directly to the substrate to create a radical
anion and/or cation respectively. These radicals then react with molecular oxygen to
produce ROS (Robertson, 2009). In Type II reactions the PS in the excited triplet state
reacts directly with molecular oxygen to produce singlet state oxygen (Robertson, 2009).
Type I and II occur simultaneously and the ratio of the two is determined by the PS,
concentration of substrate, availability of molecular oxygen, and various other factors.
Hydroxyl radicals and singlet oxygen are both very reactive and have short half live
(<0.04 µs), thus only molecules in close proximity to the ROS production site (<0.02
µm) are affected by PDT (Pervaiz and Malini, 2006).

6

Figure 2. Type I vs. Type II reaction pathway. The PS absorbs photons from light and
this energy promotes one electron from the singlet state to a high energy excited orbital.
This excited state may undergo intersystem crossing in which the spin of the excited
electrons inverts and forms an excited triplet state. This triplet state can proceed via two
routes, Type I and II reactions. (Cieplik, et al., 2014)
Modern Photosensitizers
An ideal photosensitizer will be chemically pure, chemically and physically
stable, have a short time span between administration and accumulation in tumors,
exhibit high selectively for cancerous cells, be retained preferentially by the cancerous
cells, have minimal dark cytotoxicity, be cytotoxic only upon photoactivation, have a
high quantum yield for the production of singlet oxygen, and be excreted from the body
quickly (Pervaiz and Malini, 2006; Dolmans, et al., 2003). Absorption between 600-800
nm has been deemed the optimal therapeutic window (Figure 3). Absorption and
scattering of light by tissue increase as the wavelength decreases (Ethirajan, et al.,
2011;Pandey and Zheng, 2000). Nucleic acids and amino acids are present in tissue and
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they absorb light between 250- 300 nm. Therefore, if a PS has a maximum absorbance
over 600 nm these components will have very little effect on the PS effectiveness.
Hemoglobin is the main component of tissues and is the biggest contributor to its
absorption spectrum. Hemoglobin’s absorptions peaks are all below 620 nm and those
close to 620 nm are very weak. Melanin is also contained in tissues and has a broad
absorption spectrum with strong absorption at shorter wavelengths (Ethirajan et al.,
2011,Franck and Nonn, 1995). Taking into account all of the components mentioned
which absorb below 600 nm means that light penetration is minimal at wavelengths <600
nm. Wavelengths above than 800 nm do not provide enough energy to form a sizeable
yield of ROS upon photoactivation (Ethirajan et al., 2011; Agostinis et al., 2011).

Figure 3. Optimal Therapeutic Window. Wavelength below 600nm are mainly absorbed
by nucleic acids, amino acids, melanin, and hemoglobin. Wavelengths above 800 nm do
not provide sufficient energy to generate appreciable amounts of singlet oxygen.
(Ethirajan et al., 2011; Seery, 2016)
First Generation Photosensitizers
Hematoporphyrins and HPD are referred to as first generation PS (Bonnet, 1999).
HPD have a strong absorption band at 400 nm, commonly called the Soret band, and a
four band absorption, Q band, which appears at 500, 540, 570, and 630 nm (Bonnet,
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1999). Photofrin®, was the first porphyrin based PS used in clinical trials and
subsequently the first to receive approval for use in the U.S. and Canada for the
treatments of bladder, gastric, endobronchial, brain, and esophageal cancer (Dolman, et
al., 2003). Photofrin® consists of about 60 different porphyrins (Orenstein, et al., 1996).
Woodburn et al purified the porphyrins contained in Photofrin® and determined that
porphyrins with cationic side chains localized in mitochondria and those with anionic
side chains localized in lysosomes(Orenstein, et al., 1996; Woodburn, et al., 1991).
Woodburn further investigated and determined that localization in mitochondria provided
the most cellular death Orenstein, et al., 1996; Woodburn, et al., 1991;Woodburn, et al.,
1992).
These first generation PS were effective and made from readily available
inexpensive reagents. Yet, HPD are complex mixtures that are difficult to reproduce,
have modest activity, and poor selectively. In addition, first generation PS like
Photofrin® have four to six week patient photosensitivity (Josefen and Boyle, 2008).
Furthermore, the absorption at 630 nm, is very weak and outside of the optimum
therapeutic window (Yamamto, et al., 1999, Hirth and Michelsen, 1999). The weak
absorption is compensated by using high doses of light of and drug which increases
harmful side effects (Bonnet, 1999; Jori, 1992). These drawbacks lead to the creation of
second generation PS. Many of these PS are porphyrin derivatives due to porphyrin’s
efficiency to generate singlet oxygen, lack of dark cytotoxicity, its ability to absorb light
at longer wavelengths and have intense bands above 600 nm.
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Second Generation Photosensitizers
Porphyrins. In order to capitalize on the advancements of Photofrin®, second
generation PS began with attempts to produce pure porphyrins (Figure 4a). Many
substituted porphyrins that have the lowest energy band red-shifted and/or intensified
were synthesized. m-THPP (5,10,15,20-tetraakis(m-hydroxy-phenyl)porphyrin (Figure
4b) was determined to be 25-30 times more potent than HPD. Sulfonated derivatives of
tetraphenylporphyrins (TPP) (Figure 4c) were synthesized, yet they appear to have some
neurotoxicity in rats (Bonnet, 1999).

A

B

C

Figure 4. Chemical Structure of Porphyrins. (a) Porphyrin (b) m-THPP (c) TPP
Chlorins. Chlorins (Figure 5A) have strong absorption bands in the red region
(Bonnet, 1999). They are derived from chlorophyll. They differ from porphyrin by the
absence of at least one double bond in one of the pyrrole rings in the chlorin. Visudyne®,
a benzoporphyrin derivative (BPD) (Figure 5b) is a chlorin synthesized from
protoporphyrin that has absorption at 690 nm and it is rapidly accumulated in tumors
which allow for irradiation on the same day that it is injected (Detty, et al., 2006).
Visudyne® has been approved for the treatment of wet age-related macular degeneration
in the U.S. since 2000. It has a relatively short half-life with skin photosensitization
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lasting less than a week. Foscan®, a synthetic chlorin, 5,10,15,20-tetraakis(m-hydroxyphenyl)chlorin (m-THPC) (Figure 5c) is a potent photosensitizer that was approved in
2001 for use in Europe, Norway, and Iceland (Pervaiz and Malini, 2006). The U.S. Food
and Drug Administration (FDA) rejected Foscan® in 2000 (Woodburn, et al., 1992).
Foscan® has a strong absorption peak at 652 nm, and drug and light dose are ten times
lower than HPD. Foscan® is also 25-30 times more effective than HPD, but it lacks
selectively, and has a six week skin photosensitization period which is a major drawback.

A

B

C

Figure 5. Chemical structures of Chlorins. (a) Chlorin (b)BPD (c)Foscan (m-THPC)
Phthalocyanines and related naphthalocyanines. Phthalocyanines (Figure 6b)
and naphthalocyanines (Figure 6a) have macrocyclic π-system these compounds have
strong absorption at 670 nm and 770 nm respectively. Due to their strong absorptions
only a small dose is needed (Nyman and Hynninen, 2004; Bonnet, 1995). Phototoxicty
increases when they are chelated with Zn3+ and Al3+. These metals extend the lifetime of
the triplet state (Orenstein, et al., 1996). To increase hydrophilicity, sulfonated derivates
were synthesized (Woodburn, et al., 1992). Photosens®, a sulfonated aluminum
phthalocyanine (Figure 6c), has been successfully used in clinical studies for the
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treatment of cutaneous and endobronchial lesions and head/neck tumors (Uspenskii, et
al., 2000; Sokolov, et al., 1995). Cellular uptake and phototoxicity are directly
proportional to the degree of sulfonation (Woodburn, et al., 1992). Unfortunately,
sulfonation could not be controlled, and the product is a mixture of sulfonated
phthalocyanines that could not be separated (Woodburn, et al., 1992).

a

b

c

Figure 6. Chemical Structures of Phthalocyanines and Naphthalocyanines.
(a) naphthalocyanine (b)phyalocyanin (c) Photosens® (AlPcS4).
d-Aminolevulinic acid (ALA). ALA (Figure 7a) is a naturally occurring amino
acid, and an intermediate in the synthesis of heme. During the biosynthesis of the heme
ALA is converted into proporphyrin IX (PpIX), which is phototoxic. PpIX (Figure 7b)
accumulates in tumor with slight selectivity due to the activity of two different enzymes,
ferrochelatase and porphobilinogen deaminase. Ferrochelatase is responsible for
incorporating iron into PpIX, and porphobilinogen deaminase is responsible for forming
uroporphyrin from porphobiligen (Woodburn, et al., 1992). This provides for higher
selectivity than Photofrin® but the maximum absorption is at 635 nm. Also, ALA is
hydrophilic which makes it difficult penetrate cell membranes (Woodburn, et al., 1992).
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A

b

Figure 7. Chemical Structures of ALA and PpIX. (a)ALA (b)PpIX
Although first and second generation photosensitizers are beneficial in the
treatment of cancers, they have one major disadvantage. They are not tumor selective.
These photosensitizers accumulate in both normal and cancer cells which causes severe
side effects. Therefore, a third generation of photosensitizers is currently being
investigated. This new generation of compounds will maintain or enhance the
characteristics of second generation PS, yet offer enhanced tumor selectivity.
Targeted PDT
A major problem with current cancer therapies is the low selectivity of the anticancer drug. Low selectivity of the drug allows for the toxic effects of the drug to exerted
on both healthy and cancerous tissue. PDT can be considered to have increased
selectivity over traditional cancer therapies because the toxic effects of the drug in only
induced by light, and the tissues not exposed to light will be spared the toxic effects. Yet,
some tissues that are exposed to environmental light after administering PS can exhibit
some phototoxicity that persists for several weeks after treatment. Therefore, targeted
PDT is the focus of the third generation PS. By covalently or non-covalently attaching a
targeting moiety to the PS specificity is increased. Such approaches have included the use
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of low density lipoproteins (LDL) conjugates, monoclonal antibodies conjugates,
transferrin conjugates, and macrophage scavenger receptor mediated protein conjugates.
Conjugates of PS to small molecules such as steroids, and sugars to nanoparticles have
been investigated to improve cell-type specificity in targeted PDT.
Liposomes and low density lipoproteins. Liposomes prepared with the ethoxy
castor oil, Cremphor-EL, has been used for the delivery of hydrophobic PS (Reddi,
1997). It was shown that 70-80% of hematoporphyrin that was administered in
dipalmitoylphosphatidylcholine (DPPC) liposomes became associated with lipoproteins,
while 10% of hematoporphyrin was associated with protein fraction after delivery in
phosphate buffered saline (Reddi, 1997). These studied indicated that the liposomal
hematoporphryin accumulated in the tumor at a slower rate than the free drug, but it
reached a maximum tumor concentration twice as high. Importantly, the skin
concentration was lower than the free drug (Reddi, 1997).
Proliferating tumor cells and tumor microvascular endothelial cells overexpress
LDL receptors. Thus, LDL conjugates can be used as targeting vehicles to enhance a PS
intracellular accumulation and potentially its photodynamic activity via receptor
mediated endocytosis pathway (Sharman, et al., 2004). LDLs also play an important role
in the transport of hydrophobic PS across the plasma membrane (Reddi, 1997). The
binding of serum proteins to the PS is mainly controlled by the hydrophilicity of the PS
(Reddi, 1997). Moderately hydrophobic PS have been shown to be transported in the
bloodstream by albumin, whilst highly hydrophobic are transported by lipoproteins. In
human erythrocytes, phthalocyanine-loaded LDL conjugates have been shown to induce
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cytotoxic effects by targeting specific thiol groups at the cell membrane (Martins, et al.,
2002). The efficiency and selectivity of PS delivery to LDL receptors in cancer cells
depends on the conformational change of the LDL structure. The hydrophobic Zn(III)phthalocyanine (ZnPc) PS bound to human LDL (ZnPc-LDL) exhibits low affinity for
LDL receptors and the conjugate was internalized into human HT1080 fibroblasts
through non-specific endocytosis. The lack of affinity was due to changes in the
apolipoprotein-B structure induced by phthalocyanine association in the ZnPc-LDL
conjugate (Polo, et al., 2002). To improve the incorporation of phthalocyanine-LDL
complexes, an attempt has been made to introduce a 12 carbon alkyl chain to aluminum
tetrasulfonated phthalocyanine (AlPcS4) through a sulfonamide bond (Urizzi, et al.,
2000). This conjugate showed tumor regression activity and was effective against A549
adenocarcinoma lung cancer cells (Sharman, et al., 2004; Urizzi, et al., 2000).
To enhance selectivity PS-LDL conjugates have been coupled to other targeting
moieties such as folate (Zheng, et al. 2005; Song, et al., 2007). These targeting agents
have been reconstituted into a LDL core. Transmission electron microscopy has
confirmed that these conjugates retain the size and shape of native LDL and were
preferentially taken up by tumor tissues (De Vries, et al., 1999). Although LDL has
proven to be a useful vehicle for the delivery of lipophilic drugs and diagnostic agents to
tumors, its clinical application in cancer is limited to LDL receptor related diseases
because many tumors do not over express LDL receptors (Dolmans, et al., 2003; Zheng,
et al., 2005;Fodinger, et al., 2000; Bailey and Gregory, 1999).
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Antibodies and serum proteins. To enhance tumor selectivity. Antibodies can be
used as targeting vehicles when being conjugated to PS (Mayo, et al., 2003). The
conjugation of a PS to an antibody retains the photosensitizing properties and the
conjugates bind to targeted cells more strongly than the native PS. Bhatti etal (Bhatti, et
al., 2008) introduced a system in which multiple PS were covalently attached to single
chain variable fragments. The resulting photoimmunoconjugates not only retained
photophysical properties but also were more potent than any of the individual PS with
respect to tumor cell killing capacity. Another study showed that multiply loaded
bioconjugates composed of transferrin and hematoporphyrin when combined with
luminol can significantly improve the specificity and efficiency of PDT for
erythroleukemic cells by a factor of almost seven fold (Laptev, et al., 2006). Malatesti et
al (Malastesti, et al., 2006) synthesized a cationic 5,15-diphenyl porphyrin-monoclonal
antibody (DPP-MAb) conjugates via an isothiocyanate linkage. The resulting DPP-Mab
conjugate were photodynamically inactive. Chlorin e6-monoethylenediamine monoamide
has been studied by the Hasan laboratory (Soukos et al, 1998). Theses conjugates were
synthesized with various linkers including dextran, poly-L-lysine to increase the
photosensitizer:MAb ratio. It was shown that ratios between 24-36 impaired
immunoreactivity. These compounds also showed increased tumor selectivity and
phototoxicity, yet complete removal of the tumor cells were not consistently found.
Steroids and hormones. Many steroid hormones have been conjugated to various
PS to increase selectivity, based on the hypothesis that the overexpressed steroid
receptors that in hormone-sensitive cancer cells can serve as the targeting site. Sharman
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et al. (Sharman, et al., 2004) have discussed the use and efficacy of 2-methoxyestradiol,
glucocorticoids, lovastatin, estrogens, androgens, progesterone, glucocorticosteroids,
thyroid hormones and retinoic acid (Golab, et al., 2003; Cowled, et al., 1985; Biade, et
al., 1993; Aranda and Pascual, 2001). All of these molecules can bind with high affinity
to a specifc member of the nuclear hormone receptor superfamily (Josefen and Boyle,
2008). Steroid receptors located on the nuclear membrane attracted and directed their
ligands into cancerous cells where these receptors are overexpressed.
Hormone-responsive tumor cells, especially breast tumor cells that naturally
overexpress estrogen receptor, can be targeted for the selective delivery of estrogenporphyrin conjugates for targeted PDT in breast cancer. Although many steroidphotosensitizer conjugates can effectively increase the phototoxicity within targeted
tumor cells, their low binding affinity to the targeted steroid receptors remains a problem
(Sharman, et al., 2004). High phototoxicity often associates with low selectivity, and vice
versa. For example, when chlorin e6-estradiol conjugates was introduced into the
estrogen receptor positive MCF-7 breast cancer cells, it proved to be highly photoactive
(James, et al., 1999). However, the binding affinity of this conjugate to the estrogen
receptors was about 300 times less than estradiol (Swamy, et al., 2002). One the other
hand, steroid-PS conjugates such as tetraphenylporphyrin-C11-β-estradiol can exhibit
high selectivity toward steroid receptor positive cancer cells, but is phototoxic activity
was insufficient and ineffective when being test in MCF-7 breast cancer lines (Aranda
and Pascual, 2001; James, et al., 1999, Swamy, et al., 2002). Tamoxifen (TAM), an
antiestrogen, covalently linked to pyrophenophorbide (a porphyrin derivative) via a seven
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carbon long tether. Results of the estrogen receptor (ER) binding assay showed that this
TAM-pyropheophorbide conjugates showed specific binding affinity for ERα and
displayed a strong cell killing properties in MCF-7 breast cancer cells (Fernandez, et al.,
2006). In another study, four conjugates of C17-α-alkylnulestradiol and chlorin e6dimethylester were synthesized with varying tether lengths. One of the conjugates was
efficiently taken up selectively by breast cancer cells and showed were phototoxic upon
irradiation with red light (Azria, et al., 2009; Swamy, et al., 2006).
Folate. A wide variety of photosensitizer drug carriers including liposomes,
LDLs, and small oligonucleotide fragments have been conjugated to folate and evaluated
for the effectiveness of folate receptor (FR) targeted delivery with varying degree of
success. The cell membrane FR can be used as a selective target for PS drug delivery.
The FR α isoform is usually amplified in epithelial cancers, while over expression of the
FR β isoform is commonly found in myeloid leukemia and activated macrophages
associated with chronic inflammatory disease (Zhao and Lee, 2008). Conjugates of folic
acid can be taken up by cancer cells via receptor mediated endocytosis (Reddi, 1997).
These conjugates have been shown to enhance the uptake ratio and antitumor activity of
the PS both in vitro and in vivo. One of the problems with most PS currently used in PDT
clinical trial is their low tumor-to-normal epithelial uptake ratio. This is especially the
case with m-THPC. In order to overcome this limitation, Gravier et al. (Gravier, et al.,
2008) have reported on the synthesis of an m-THPC-like photosensitizer conjugated to
folic acid. Using optical fiber fluorimetry, the enhanced selective accumulation of this
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conjugate was demonstrated in FR α positive KB mouse tumor cells 4 h after injection
and the resulting tumor-to-normal tissue ratio was 5:1.
FR-mediated liposomal delivery has also been shown to enhance antitumour
efficacy of the photosensitizer doxorubicin both in vitro and in vivo (Pan and Lee, 2004).
These FR-targeted liposomes could serve as carriers directing many genes and antisense
oligodeoxyribonucleotides to FR-positive tumor cells. Both solid tumors and leukemia
can potentially benefit from this approach (Reddi,1997; Pan and Lee, 2004). Studies have
also demonstrated the role of folic acid conjugation in rerouting the resulting conjugate
bearing an LDL carrier molecule from its natural receptor to cancer cells through folate
receptors (Glickson, et al., 2009; Preise, et al., 2009).
Vascular targeted-PDT. To induce tumor growth, tumor tissues need to develop a

vascular system based on existing host blood vessels for nutrients delivery and the
removal of metabolic wastes. Vascular-targeted photodynamic therapy (VTP) makes use
of the intravascular excitation of PS to produce cytotoxic ROS, which are the mediators
through which VTP initiates acute local inflammation inside the illuminated area
accompanied by tumor cells death (Reddi, 1997). Unlike other PDT techniques, PS used
in VTP are activated in the vasculature. Various mechanisms of VTP-mediated tumor
eradication through immune response induction has been examined. Using the PS WSTII, Preise et al. (Fleshker, et al., 2008) has shown that long-lasting systemic antitumor
immunity was induced by VTP that activates both cellular and humoral components and
that VTP can be used in conjunction with immunotherapy for the enhancement of host
antitumor immunity. To increase the overall success rate of VTP, an assessment for
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successful VTP of solid tumor 24 h post treatment is needed to allow for a second
treatment in case of failure. For example, the treatment of carcinoma tumors in mice by
VTP with the photosensitizer WST-II was used to enable fast assessment of treatment
success after 24 h. The mice that signified treatment failure, featuring various levels of
subsequent tumor re-growth, were treated again and the overall successful VTP rate
increased to over 90% (Eggener and Coleman, 2008). Two common vascular-targeting
photosensitizers being clinically used today are verteporfin and palladium
bacteriopheophorbide (WST09 or Tookad) (Trachtenberg, et al., 2008). It was shown that
Tookad-VTP can produce large avascular regions in the irradiated prostate, resulting in a
complete negative biopsy response at high light doses (Di Stasio, et al., 2005).
Lectins and saccharides for PS conjugates. Lectins are cell adhesion molecules
that have been known to play a role in recognizing cell surface carbohydrates of cancer
cells, including liver, breast, prostate, lung, and bile duct cell types. Thus, they are
popular targets for developing glycoconjugated photosensitizer drugs (Frochot, et al.,
2003). Cancer cells generally overexpress monosaccharide transporters at the surface of
their plasmic membrane (Taquet, et al., 2007). This will allow for increased PS solubility
and enhanced selectivity. Mono-glucosylated porphyrins and mono-glucosylated chlorin
e6 have been shown to accumulate mainly inside the endoplasmic reticulum in human
colon adenocarcinoma cell line HT29. Improved cellular uptake and increased
photodynamic activity in terms of singlet oxygen quantum yield and a high extinction
coefficient value were also demonstrated (Zheng, et al., 2001; Chen, et al., 2004). In
another experiment, β-galactose was conjugated to the PS, purpurinimides. This PS-
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saccharide complex is recognized by galectin-l in vitro and exhibits an increase in
photodynamic efficacy (Hamblin, et al., 2000). Non-hydrolyzable saccharide-porphyrin
conjugates have also been synthesized using a tetra(pentafluorophenyl)-porphyrin and a
thiol sugar derivative. These saccharides-porphyrin conjugates showed a varying degree
of PDT success across different types of malignant cancer cells (Sutton, et al., 2002).
Targeting with peptides. Peptides are of interest for targeted PDT due to their
cell penetrating properties and their affinity to specific receptors (Taquet, et al., 2007).
Peptide-PS generally retain the photophysical properties of the PS, yet the quantum yield
of singlet oxygen is often lowered (Taquet, et al., 2007). The arginine-glycine-aspartic
acid (RGD) peptide motif has been shown to improve PDT targeting efficiency and
reduce the side effects of accumulated photosensitizers in non-target tissue (Taquet, et
al., 2007). RGD conjugated to tetraphenylchlorin (TPC) was shown to be internalized 80100 more times than TPC alone after 24 h and it was shown to bind specifically to the
overly expressed avß3 integrin on the surface endothelial cells in tumor neovasculature.
But the RGD-TPC had a two-fold decrease in singlet oxygen production. Cyclic RGD
peptide conjugated to photosenstizer PpIX was shown to have an increase cell
accumulation over PpIX, but when tested in vivo it accumulated in the liver and did not
enhance PDT (Taquet, et al., 2007). In another study, Frochot et al. (Zheng, et al., 2001)
synthesized a conjugate of porphyrin and the avß3 integrin specific peptide RGD. The
higher photodynamic efficiency observed was correlated with greater cellular uptake of
the conjugate. In vitro results have confirmed that PS with linear or cyclic RGD motifs
are much more potent in targeting tumor endothelial cells due to its high affinity to avß3
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integrin receptors commonly found in many types of cancer and may potentiate the effect
of vascular PDT in vivo as well.
The RGD motif has also been employed in PDT that involves tumor targeting
with adenoviral proteins because the penton base of the adenovirus type 2 capsid protein
contains the RGD sequence. Allen, et al. (Taquet, et al., 2007) has covalently coupled the
PS tetrasulfonated aluminum phthalocyanine (AlPcS4) to various adenovirus capsid
proteins, and the AlPcS4A protein complex has been shown to induce greater
phototoxicity than the unconjugated AlPcS4A. This suggests that the high affinity
RGD/receptor complex can be potentially used as another targeting vehicle to deliver
photosensitizers to the appropriate tumor cells.
Peptides can also be used to target a specific subcellular compartments. Nuclear
localization sequence (NLS) has been used to target the nucleus although attempts to
detect the PS-NLS in the nucleus have failed (Taquet, et al., 2007). A major issue with
PS-peptide conjugates in vivo is their lack of stability in the bloodstream (Taquet, et al.,
2007).
Nanoparticles. Two general strategies exist for using nanoparticles as a
photosensitizer carrier system. The first is using biodegradable nanoparticles, made of
polymers readily degraded in a biological environment, in which the photosensitizers
can be released from the nanoparticle and irradiated to produce single oxygen. The
secondly strategy is to use non-biodegradable nanoparticles in which the photosensitizer
is not necessarily being released from the system, but the singlet oxygen could diffuse
freely in and out of the nanoparticle carrier system (Spenlenhauer, et al., 1989).
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One of the most commonly used biodegradable nanoparticle is the aliphatic
polymer poly(DL-lactic-co-glycolide) (PLGA) nanoparticle. The mechanism of which
involves a size-dependent hydrolytic process. Nanoparticles of less than 300 µm in
diameter undergo a homogeneous degradation while larger particles show a
heterogeneous degradation in vivo and in vitro (Gomes, et al., 2005). Polymeric PLGA
nanoparticles have been loaded with various PS including bacteriochlorophyll-a (BChla) (Gomes, et al., 2007; McCarthy, et al., 2005), p-THPP, m-TPPPL, m-TTP (RicciJunior and Marchetti, 2006), zinc(ll) phthalocyanine (ZnPc) (Zeisser-Labouebe, et al,
2006), hypericin (Hy) (Kopelman, et al., 2005). The delivery process has been shown
taking place in two steps: (1) adhesion of the particles to the cell surface followed by
(2) the release of the PS, which caused detectable photodamage of the targeted cellular
surface after laser irradiation (Bechet, et al., 2008). PLGA nanoparticles loaded with pTHPP achieved vascular targeted PDT, they are limited in their loading capacity
(Taquet, et al., 2007). In addition, these nanoparticles lose their PS content in aqueous
solution at a steady rate (Taquet, et al., 2007).
Many non-degradable nanoparticles have also been synthesized, although their
application in targeted PDT is still limited. The ability of non-biodegradable
nanoparticles to serve as multifunctional platforms proved to be quite effective in the
diagnostic and treatment of cancer. For example, in a brain cancer study (Sutton, et al.,
2002), a non-degradable polyacrylamide nanoparticle platform containing Photofrin®
with a PEG surface coating, and the cellular targeting agent (the integrin-targeting RGD
peptide) was synthesized. This multifunctional nano-platform was capable of diagnosing
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brain cancer due to the presence of an associated magnetic resonance imaging (MRI)
contrast enhancer. In in vivo experiments, the MRI contrast agent could be used to
monitor changes in tumor diffusion, tumor growth and tumor load (Ahmad and Mukhtar,
2000). Treatment with this PS-nanoparticle system was followed by irradiation of the PS
and tumor necrosis (Sutton, et al., 2002; Ahmad and Mukhtar, 2000). Most nondegradable nanoparticles are silica-based or metallic-based. One advantage of metallicbased nanoparticles, in contrast to their silica-based counterparts, is that they can be
confined to an extremely small particle size of only a few nanometers while their large
surface area can facilitate a large number of photosensitizer molecules, which resulted in
an increased singlet oxygen diffusion (Doughtery, et al., 1998).
Folate Directed, Protein Based Targeted PDT
Our laboratory aims to develop a third generation PDT agent that will provide
increased selectivity for tumor cells, and a greater concentration of PS at the site of
action, using a L.E.D. light source. We will generate folate directed PDT agents that will
target the FR on cancerous cells. Many cancers overexpress the FR, therefore attaching
folate to a PS should enhance selectivity, and delivered into the cell via receptor mediated
endocytosis.
In addition to poor specificity, the light needed to activate many PDT agents can
only penetrate tissues between 0.5-3 cm. This drastically limits the types, size, and
location of cancers that can be treated. Utilizing a PS that has absorbances in the
optimum therapeutic window, 600-800 nm, with high extinction coefficients, will allow
for deeper tissue penetration of light and enough energy to produce singlet oxygen. Our
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PS of choice is Chlorin e6 (Ce6), a relatively inexpensive commercially available dye.
Ce6 will lead to significant cellular death due to its absorption maxima at 660nm and
corresponding high extinction coefficient of 59,000 M-1cm-1 at that wavelength. This will
allow for deeper penetration into cells and higher generation of singlet oxygen.
We will use bovine serum albumin (BSA) as our carrier. Folate and Ce6 will be
covalently bound to BSA through amidation reaction. The incorporation of BSA will
increase solubility and reduce hydrophobicity.

CHAPTER TWO
PURPOSE OF RESEARCH
The main objective of this research is to develop a folate-directed, protein-based
photodynamic therapy agent to treat cancerous tumors and to show their effectiveness in
cell culture and in vivo. We aimed to develop novel photodynamic therapy (PDT) agents
that specifically target cancerous cells. PDT utilizes oxidative damage to kill these cells.
Light excites a photosensitizer, which then reacts with oxygen to form a highly reactive
oxygen species, singlet oxygen. This singlet oxygen reacts with cellular macromolecules
to cause lethal damage (Vrouenraets, et al., 2003). We hypothesize that folate (FA)
conjugation to a photosensitizer will increase the agent’s specificity. Folate receptors are
overly expressed in epithelial, ovarian, cervical, breast, lung, kidney, colorectal, and brain
tumors (Zwicke 2012; Parker 2005) Therefore, FA-PDT has double selectivity due to the
combination of folate-targeting plus limited-area light exposure. The folate containing
conjugate can be taken up by the cell into the cytoplasm via receptor mediated
endocytosis.
In addition to poor tissue specificity of many PDT agents, the light needed for
excitation can only penetrate tissues between 0.5-3cm (Vrouenraets, et al., 2003). This
drastically limits the types, size, and location of cancers that can be treated. Utilizing a
photosensitizer that have absorbances at longer wavelengths in the optimum therapeutic
window, 600-850 nm, with high extinction coefficients, will allow for deeper tissue
25
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penetration of light and enough energy to produce singlet oxygen (Vrouenraets, et al.,
2003). We hypothesized that using chlorin e6 (Ce6), a relatively inexpensive
commercially available dye, as a photosensitizer will lead to significant cellular death.
Ce6 has an absorption maximum at 660 nm and corresponding high extinction coefficient
of 59,000 M-1cm-1 at that wavelength (Dolmans, et al., 2003). This will allow for deeper
penetration into cells and higher generation of singlet oxygen.
Both FA and Ce6 are hydrophobic therefore, we hypothesize by covalently
attaching FA and Ce6 to bovine serum albumin (BSA), hydrophilicity will increase
making conjugation chemistry more efficient and delivery to cancerous tumors easier.
We choose BSA due to its relative stability, low cost, ease of purification, and its high
number of lysine residues. BSA has between 30-35 free lysines, whose primary amine
residues can react with the carboxyl groups, 2 and 3, respectively on FA and Ce6 to form
a stable amide bond. The large number of sites of conjugation provides a platform to
deliver a greater of number of Ce6 to the cancerous tumor.
HeLa cells are an immortal cell line that was derived from cervical cancer cells.
This cell line is commonly used in cancer research along with a host of other scientific
quests. Low and Leamon proved in 1991 that the folate receptor on HeLa cells can be
exploited to deliver folate conjugated macromolecules into the cytoplasm via receptor
mediated endocytosis. They also proved that macromolecules in the range of 13.7 kDa
(RNase) to 443 kDa (ferritin) can be internalized into HeLa cells via the folate receptor.
Therefore, we hypothesize that our folate targeted compound, FA-BSA-Ce6, which is
well within the size range they explored, should be able to be internalized into HeLa
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cells, thus making HeLa cells a viable option for cell culture studies. We will explore
both concentration and light energy, to determine optimal experimental conditions.
In addition to cell culture, this dissertation will also discuss the use of zebrafish
for targeted PDT. During embryogenesis zebrafish undergo rapid cell division, which can
be used as a model for cancer. Zebrafish provides a high throughput organism for in vivo
studies, as well as their transparent nature allows for insight that cannot be achieved with
cell culture alone. This use may lead to a new tool for studying zebrafish development.
This body of work details the synthesis and characterization of folate targeted,
protein based conjugates, their efficacy in HeLa cell culture, the elucidation of the gene
expression pattern and confirmation of the folate receptor in zebrafish, and the selective
targeting of cells during the first 5 days post fertilization of zebrafish embryos.

CHAPTER THREE
BSA BASED, FOLATE DIRECTED PHOTODYNAMIC THERAPY AGENT’S
EFFECTIVENESS IN HELA CELLS
Introduction
Chemotherapy is one of the most popular course of treatment for cancer. It is
often coupled with radiation and/or surgery as a two pronged approach to eradicating the
cancer. There are over 100 chemotherapy drugs available and most work by stopping or
slowing the growth of rapidly dividing cells throughout the body. This robustness makes
chemotherapy very effective against cancerous cells yet it also provides an avenue for
healthy cells to be negatively affected. This leads to numerous unwanted side effects. As
an alternative to chemotherapy or a method to use less chemo drugs, photodynamic
therapy (PDT) has become an attractive option. PDT utilizes oxidative damage to kill
cells. Light excites a photosensitizer (PS), which activates oxygen to form highly
reactive oxygen species (ROS), including singlet oxygen, 1O2. ROS then reacts with
cellular macromolecules to cause lethal damage (Ahmad and Mukhtar, 2000). In the
ground state PS have two paired, opposite spin electrons. Upon light activation, one
electron is promoted to a higher energy orbital, and the PS becomes excited (Robertson,
2009). The PS can return to a relaxed state by emitting energy as fluorescence. Another
option is for the PS to undergo intersystem crossing. Intersystem crossing takes the PS to
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an excited triplet state and from there the PS can participate in two types of reactions
Type I and Type II (Robertson, 2009). Type I reaction involves the excited PS
interactingdirectly with a substrate, such as the cell membrane. In this case a hydrogen
atom is transferred and radicals are formed. These radicals interact with molecular
oxygen to form reactive oxygen species (Robertson, 2009). In Type II reactions the
excited PS transfers its energy directly to oxygen to form singlet oxygen, 1O2 (Robertson,
2009). This 1O2 is toxic to cells and leads to cellular death. Type II reactions are the most
beneficial to combat cancerous cells because the oxygenated products that are produced
are more predictable and leads to direct death of the intended cell (Robertson, 2009).
Currently Photofrin® (Porfimer sodium) is the most widely used, FDA-approved
PDT drug for cancer. Photofrin® is a second generation PS that is comprised of a mixture
of hematoporphryin derivatives. Photofrin® is used to treat esophageal and
endobronchial cancer. It absorbs light at 635 nm and it is not very selective for cancerous
cells. This is the case for most of the approved PDT drugs. Many of them have significant
limitations, primarily low specificity, which causes harm to bystander cells (Dougherty,
et al.., 1998). They rely on differences in physical properties, such as cellular pH, to
discriminate between healthy and cancerous cells which leads to poor targeting of tumor.
In addition, as is the case with Photofrin®, the light needed to excite many PDT agents
only penetrates tissues to a depth between 0.5-3cm beneath the skin (Fuchs and Thiele,
1998). This limitation leads to significant limitation of the types, size, and location of
cancers that can be treated.
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Utilizing a photosensitizer that has absorption at longer wavelengths in the
optimum therapeutic window, 600-850 nm, with high extinction coefficients, will allow
for deeper tissue penetration of light and enough energy to produce singlet oxygen (Fuchs
and Thiele, 1998). Chlorin e6 (Ce6), a relatively inexpensive commercially available dye,
as a photosensitizer will lead to significant cellular death. Ce6 has an absorption
maximum at 660 nm and corresponding high extinction coefficient of 59,000 M-1cm-1 at
that wavelength (Oseroff, et al.., 1986). This will allow for deeper penetration into cells
and higher generation of singlet oxygen.
To increase selectivity and effective we propose using folate (FA) as a targeting
agents for the PS, Ce6. Many malignant cells overexpress folate receptors in order to
support its rapid cell division and growth (Bisland, et al.., 1999). FA conjugation to a PS
will increase the agent’s specificity. Therefore, FA-PDT has double selectivity due to the
combination of folate-targeting plus limited-area light exposure. The folate containing
conjugate can be taken up by the cell into the cytoplasm via receptor mediated
endocytosis.
Both FA and Ce6 are hydrophobic. Therefore, in order to increase solubility and
reduce hydrophobicity as well as provide a scaffold for multiple molecules of Ce6 to be
delivered to the cancerous cells, we covalently linked FA and Ce6 to bovine serum
albumin (BSA).
Materials and Methods
Reagents.1-ethyl-3-(3dimethylaminopropyl)carbodimide (EDC), bovine serum
albumin (BSA), anhydrous dimethyl sulfoxide (DMSO), ethanolamine, fetal bovine
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serum, folate (FA), Hepes buffered saline (HBS), N-hydroxysuccinimide (NHS), Roswell
Park Memorial Institute (RPMI), and trypsin/EDTA were purchased from Sigma
Chemical Company (St. Louis, MO). Chlorin e6 (Ce6) was purchased from Frontier
Scientific (Logan, UT). Cell Titer Blue Assay was purchased from Invitrogen (Grand
Island, NY). HeLa cells were obtained from Dr. Stefan Kanzok’s laboratory at Loyola
University Chicago. All other chemicals used were analytical grade and used without
further purification, unless otherwise specified.
Synthesis of BSA-Ce6, BSA-FA, & FA-BSA-Ce6. Ce6 and FA both contain
multiple carboxyl groups (three and two respectively). BSA is a 67 kDa single
polypeptide that has 60 lysine residues. Of the 60 lysine residues, 30-35 are available to
react (Huang and Kim, 2004). Carbodiimides are commonly used to activate carboxyl
groups for conjugation to primary amines. EDC is a water soluble carbodiimide that
creates a zero length linker between carboxyl and amine groups. EDC coupled with NHS
reacts with the carboxyl groups on Ce6 and FA to form a semi-stable NHS- ester
intermediate (Han and Kim, 2004). The lysine residues (primary amine) on BSA reacts
with the ester intermediate to form an amide bond (Montalbetti and Falque, 2005).
Ce6 was placed inside of a 1.5 mL microcentrifuge tube that was covered with
foil. The dye was dissolved in 200-300 μl of dry DMSO. Next, it was incubated with a
10-fold molar excess of EDC and a 20-fold molar excess NHS at room temperature for
30 min. A 20-fold molar excess of the esterified Ce6 was added dropwise to BSA
(10mg/ml) that was previously dialyzed in bicarbonate buffer at pH 8.0 The mixture was
incubated for 24 h at room temperature and quenched with ethanolamine. FA-BSA was
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prepared in the same manner as BSA-Ce6 with the only exception being that a 10-fold
molar excess of FA was added to BSA. The excess Ce6, FA, NHS and ethanolamine was
removed by dialyzing overnight in phosphate buffered saline (PBS) at pH 7.4.
The synthesis of FA-BSA-Ce6 (Figure 8), begins with preparing BSA-FA as
described above. BSA-FA was exhaustively dialyzed in bicarbonate buffer at pH 8.0.
Post dialysis a 5, 10, 15, 20, or 30 fold molar excess of esterified Ce6 was added to
aliquots BSA-FA to determine the optimum Ce6:BSA ratio. The mixtures were incubated
for 24 h at room temperature. The excess Ce6, NHS and ethanolamine was removed by
dialyzing overnight in PBS at pH 7.4.

Figure 8. Conjugation Schematic. Addition of Folic Acid/Chlorin e6 to BSA. Carboxyl
groups on folic acid are esterified by reacting with EDC/NHS. The newly formed ester
reacts with the amine on the lysine residues of BSA to form an amide bond.
Characterization of conjugates. An acid-acetone precipitation was carried out
on FA-BSA, BSA-Ce6 and FA-BSA-Ce6 to quantify the number the folates and dyes
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covalently bound to the protein (Hamblin, et al.., 2000). Briefly, 500 µl of conjugate was
added slowly while stirring to 5 mL of acidic acetone at 4°C for 4 h. The sample was
centrifuged at 4000 g at 4°C for 10 min. After centrifuging the supernatant was discarded
and the pellet was reconstituted in 5 mL of cold acetone, and centrifuged. The
supernatant was visually inspected after each round of precipitation/centrifuging for hues
of green and/or yellow. If the supernatant appeared colored, the sample was subjected to
another round of precipitation. After four rounds of precipitation, an absorption spectrum
was taken of the supernatant between 220 nm – 900 nm. The spectrum was analyzed for
any significant peaks, paying close attention to the Ce6 maxima at 400 nm and 660 nm,
and folate absorption maximum at 363 nm. This step was repeated until the spectra
showed no significant peaks above baseline. The remaining pellet was reconstituted in
1.5 mL of PBS at pH 7.4 and dialyzed against PBS at pH 7.4 for 18h to remove any
remaining acetone. An absorption spectra was taken of the dialyzed pellet, which
contains the conjugate, and after correcting for BSA’s slight contribution to the folate
peak at 363 nm the number of FA and Ce6 molecules covalently attached to the protein
was determined using folate and Ce6 maxim um absorptions, 363nm and 660nm
respectively, and corresponding extinction coefficients of 6,197 mM-1cm-1 for folate
(Kranz, et al.., 1995) and 59,000 mM-1cm-1 for Ce6 (Oseroff, et al., 1986) .
Determination of ROS production. Photoactivation of Ce6 leads to the
production of singlet oxygen (1O2) which is a reactive oxygen species (ROS)
(Wawrzynska, et al.., 2010). ROS is considered to be integral in apoptotic and necroctic
pathways. Ce6 has been studied for many years and is purported to have a high quantum
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yield of O2 (Douillard, et al.., 2009; Nelson, et al.., 1987, Qian, et al.., 1987; Mojzisova,
1

et al.., 2007).To determine if FA-BSA-Ce6 maintains 1O2 production, ρ-nitroso-N, N′dimethylaniline (RNO) was used as a singlet oxygen sensor. The production of singlet
oxygen was monitored by bleaching RNO at 440nm. A 250 μM RNO and 0.03M
histidine solution was made in D2O. D2O was included to assist in extending the lifetime
of 1O2 (Klotz, et al.., 1997). 6 µM of unconjugated Ce6 or FA-BSA-Ce6 were dissolved
in separate vials of 700 μl of 1% DMSO in D2O to maintain solubility of unconjugated
Ce6. Each solution was added to the RNO solution and bubbled with water-saturated
oxygen for 10 min. The mixture was placed in a quartz cuvette and irradiated with 44.9
J/cm2 (8 min) with an 660 nm LED lamp. The absorption at 440 nm (λmax of RNO) was
monitored every 30 s using a UV-Vis spectrophotometer (Krajlic, et al.., 1978; Mosinger
and Zdenek, 1997; Muller-Breitkreutz et al.., 1995).
Dark cytotoxicity & phototoxicity. HeLa cells were maintained in Roswell Park
Memorial Institute (RPMI) media (pH 7.4), supplemented with 10% fetal bovine serum
(FBS), 2 mM glutamine, and 10 mM HEPES, at 37°C with 5% CO2. Prior to treatment
the medium was switched to folate deficient RPMI medium. Cells were seeded at an
initial density of 10,000 cells per well in black-walled 96-well plates. Following seeding
cells were exposed to the conjugates, BSA-Ce6 or FA-BSA-Ce6, at a Ce6 concentration
of 1, 2, 5 and 10 µM respectively and incubated for 24 h in the dark. After incubation the
folate-deficient medium was removed and after several washes the cells were placed in
folate-containing-RPMI. The cells were then irradiated with a LED lamp (660 nm) for 1,
2, 4, and 6 min, respectively to deliver 5.6, 11.2, 22.5 and 33.7 J/cm2 respectively. In
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parallel, an identical control plate was kept in the dark. After incubating for 24 h cell
viability was determined using Cell Titer Blue Assay Kit (Promega).
Statistical analysis. Two-tailed student’s t test was used to identify significance
between means. The level of significance was set to p <0.05. All values stated are
reported as the mean +/- standard deviation from the mean.
Results
Quantification of folates and chlorin e6 molecules bound to BSA. Slight
modification of published protocols for carboxyl to amine amide bond formation
(Leamon and Low, 1992), BSA-Ce6 and FA-BSA-Ce6 conjugates were synthesized via
exposed lysine residues in BSA and free carboxyl groups on Ce6 and FA (Figure 8). BSA
(10mg/ml) was conjugated to folic acid (FA) using a 10 molar excess of FA to protein.
Based on the absorbance after dialysis at FA maximum absorption wavelength 368 nm
and corresponding extinction coefficient of 7410 mM-1cm-1 (Kranz, et al.., 1995) the
number of folates covalently bound was determined to be two. Ce6 has an absorption
maximum at 660 nm and corresponding extinction coefficient of 59,000 M-1cm-1
(Oseroff, et al.., 1986) at that wavelength. A UV-vis spectra was taken after the final
dialysis, and the number of Ce6 molecules covalently attached to FA-BSA was
determined. As shown in Table 2, 5:1, 10:1, 20:1 and 30:1 ratio of Ce6 to protein
produced four, six, ten, and ten molecules covalently attached respectively.
Porphryin based dyes, such as Ce6, can potentially strongly interact noncovalently with serum proteins (Mew, et al.., 1983). To ensure that all excess Ce6
molecules in addition to FA were removed an acetone extraction was also performed on

36
each of the conjugates. After conjugation, an aliquot was added dropwise to cold acetone,
and the pellet was analyzed via absorption spectroscopy. The resulting number of FA and
Ce6 that were determined to be covalently attached matched the results from exhaustively
dialyzing the conjugates. Based on the results, acetone extraction was deemed to be
unnecessary and the conjugates were dialyzed in PBS post conjugation. Based on the
results, a ratio of 20:1 was used for FA-BSA-Ce6 synthesis.
Ce6:BSA

# of Ce6

5:1

4.2

10:1

6.3

20:1

10.4

30:1

10.3

Table 2. Number of Dye Bound. The number of Ce6 molecules was determined using
varying rations of photosensitizer to protein. Ten molecules were covalently attached
using 20:1 and 30:1, therefore, 20:1 was chosen.
Singlet Oxygen Production due to photoactivation. Ce6 produces a significant
amount of singlet oxygen (Fernandez, et al.., 1997). To determine if Ce6 maintains its
output of singlet oxygen once conjugated to FA-BSA, samples of FA-BSA-Ce6 and Ce6
(both samples contained the same Ce6 concentration) were mixed with RNO (a singlet
oxygen quencher) and was irradiated with a L.E.D. lamp at 660 nm for 8 min. An UVVis spectra was taken every 30 s monitoring the absorption at 440 nm (Figure 9). As
singlet oxygen is quenched by RNO, there is a reduction in the absorption at 440nm. The
decrease in the peak was monitored until the absorbance was around 0.100.
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Figure 9. Singlet Oxygen Produced from FA-BSA-Ce6. Singlet oxygen quencher, RNO,
was used to monitor the production of singlet oxygen of FA-BSA-Ce6 upon irradiation at
660nm between 0 min and 8 min.
FA-BSA-Ce6 dark cytotoxicity. The cells were exposed to the conjugates for 24
h, washed and then incubated for another 24 h, after which cell viability was measured
using Cell Titer Blue Assay Kit (Figure 10), a fluorescence assay in which viable cells
exhibit a higher fluorescence than non-viable cells. Percent survival was determined by
comparison to cells exposed to media only. BSA-Ce6 at a concentration of 10 µM had a
98% (+/- 5 %) cell survival rate. FA-BSA-Ce6 at 1µM, 2 µM, 5 µM, and 10 µM
concentrations were also assayed for dark cytotoxicity. The respective survival rates were
as follows: 100 % (+/- 2 %), 93 % (+/- 1.5 %), 98 % (+/- 3 %), 98 % (+/- 2 %) (Figure
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10). There was no statistical difference between media only cells (control) versus any of
the test wells. All of the conjugates cell survival rates were above 93% when compared to
control.
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Figure 10. Dark Cytotoxicity Results of Conjugates and Controls. Based on control cells
all conjugates are not significantly different.
Cell death via photoactivation of FA-BSA-Ce6. The viability of media only
cells was set at 100%, and all conjugates are reported in comparison to those cells. Cell
viability for 1µM, 2 µM, 5 µM, and 10 µM FA-BSA-Ce6 was assayed at 5.6, 11.2, 22.4,
and 33.7 J/cm2 of light, in addition to 10 µM BSA-Ce6. Across all times of light
irradiation BSA-Ce6 maintained above 92% cell survival (Figure 11).
No significant cell death resulted for 1µM of FA-BSA-Ce6 at any of the
irradiation energies. The lowest viability for FA-BSA-Ce6 at 2 µM was 74% with 2
minutes of light irradiation. This was the lowest viability for that concentration, which
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was significantly different than at 1 minute, but not significantly different from 4 minutes
of light (based on standard deviations).
While the lowest viability for FA-BSA-Ce6 at 2 µM was 74% with 2 min of light,
the highest viability for both 5 µM and 10 µM FA-BSA-Ce6 was 76% with 1 min of
light. 5 µM and 10 µM samples show significant difference from the controls starting at 2
minutes of light, yet they do not show any statistical difference from one another for the
other light energies (Figure 12). 5 µM FA-BSA-Ce6 caused the most cell death with 4
min of light which resulted in 5.3% cell survival. 10 µM FA-BSA-Ce6 caused the most
cell death at 4 min light as well, which resulted in 3.9% cell survival.

Figure 11. Phototoxicity of Controls: BSA or BSA-Ce6 showed significant cell death in
comparison to cells exposed to media only.

Figure 12. Phototoxicity of FA-BSACe6: Results of FA-BSA-Ce6 at varying concentrations and light
irradiation times.
40
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Discussion
An effective photodynamic therapy agent will be phototoxic but not cytotoxic in
the dark. In an attempt to maximize the efficiency of Ce6 conjugation to BSA we varied
the ratio of Ce6:BSA. There was a lack of increase in Ce6 conjugation with 30:1 ratio in
comparison to 20:1. In 2004 Huang and Kim reported on the use mass spectrometry
coupled with lysine specific cross-linkers to analyze the tertiary structure of BSA. In their
study the were only able to crosslink 34 of the 60 lysines that are present in BSA (Huang
and Kim, 2004). The lack of increase in Ce6 conjugation with 30:1 vs 20:1 ratio could be
due to steric hindrance of the available lysines. Thus, a 20:1 ratio of Ce6 to protein was
chosen, and based on UV-Vis spectra conjugation of both folate and Ce6 was successful.
To ensure that Ce6 maintained its ability to produce singlet oxygen, its production
of singlet oxygen was monitored via a singlet oxygen quencher. The results from this
experiment confirmed that upon conjugation to FA-BSA, Ce6 produces singlet oxygen.
The effectiveness of FA-BSA-Ce6 as a photodynamic therapy agent was
examined in comparison to media-only cells and BSA-Ce6 (Figure 11). BSA-Ce6 was
shown to not be phototoxic or cytotoxic at 10 µM concentration and at all light intensities
assayed. This is a significant finding because free Ce6 at significantly lower
concentrations have been proven to be cytotoxic and we report 98% cell survival rate of
BSA-Ce6. Conjugating Ce6 to BSA increases its solubility and decreases it
hydrophobicity. This is the most apparent reason why BSA-Ce6 did not show any
significant cell death, while in the literature Ce6 demonstrates cytotoxicity.
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As shown in Figure 12 cell survival is both concentration and light dose
dependent. As the concentration of FA-BSA-Ce6 increase and as light exposure time
increases, cell survival decreases. Interestingly, the same effects are not seen with BSACe6 (Figure 11). Light irradiation time does not affect percent survival. The only
difference between the two conjugates is the targeting moiety, folate. This data
combined with the ROS production data, it can be concluded that the conjugate is being
taken up via receptor mediated endocytosis.
We have demonstrated that conjugation of FA and Ce6 to BSA provides an effective
PDT agent that is specifically taken up into the cells via receptor mediated endocytosis.
The conjugate is both dose time and concentration dependent. Thus the higher the
concentration and the longer light irradiation, the less cell survival. Concentrations less
than or equal to 2 µM are not effective at killing cells in culture. In contrast there is no
benefit in using 10 µM FA-BSA-Ce6 due to 5 µM FA-BSA-Ce6 providing essentially the
same magnitude of cell death. FA-BSA-Ce6 offers potential benefits not seen with
approved PDT agents. The main difference presented is the ability to target cells that
upregulate the folate receptor. Thus combining limited light area exposure and the
targeted conjugated, FA-BSA-Ce6 offers double selectivity.
In 2015 Donghong Li et al. synthesized a new a m-tetra(Hydroxyphenyl)chlorin
(m-THPC) derivative based PS called, PS1, and covalently attached folate to PS1 via
PEG. m-THPC is approved for use in Europe, Norway, and Iceland as PDT agent under
the name Foscan (5). m-THPC has a maximum absorption at 650 nm and without a
targeting moiety such as folate, it demonstrates poor selectively. Li reported on improved
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tumor selectively over m-THPC without folate. HeLa cell culture experiments with 15.2
µM PS1 and light dosages up to 36 J/cm2 resulted in cell viability for all light dosages
above 10%. When the concentration was varied up to 147 µM and the light was constant
at 18 J/ cm2, cell viability was above 20% for all concentration tested. Using almost three
times less of PS, and three times less light, our 5 µM FA-BSA-Ce6 with 11.2 J/cm2 of
light, produced similar results.
In another study folate-targeted PEGylated liposomes with m-THPC were
synthesized and tested for its effectives as a PDT agent (Moret, et al., 2013). In this study
the results for phototoxicity in KB cells were significantly better than m-THPC alone and
the work PS1. Liposomes have previously been shown to be a good encapsulator and
carrier of m-THPC (Moret et al., 2013). Moret and colleagues synthesized two m-THPC
liposome conjugates with two different PEG lengths. While no increase of uptake of was
seen with the smaller 2000 kDA PEG over a zero length linker, uptake was increased
with the larger 5000 kDa PEG. Their folate targeted conjugate produced less than 10%
cell survival with only 2.4 µM of conjugate and .8 J/cm2 of light. This is a significant
improvement in comparison to our conjugates and PS1. But, they also discovered that the
untargeted and targeted conjugates produced similar phototoxicity. Un-targeted, BSACe6 was not phototoxic to cells.
Lee and Low showed that PEG lengths can affect the photo-killing capacity and
uptake of PDT agents. PS1 was synthesized with a 75 kDa PEG and produced little cell
death in comparison to Moret and colleagues conjugate. Laura Donahue and colleagues
(unpublished) has synthesized a 2000 kDa FA-PEG-Ce6 PS that shows promise as a good
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PDT agent at lower concentration than FA-BSA-Ce6, yet FA-PEG-Ce6 showed some
cytotoxicity in the dark. Based on these findings with PEG linkers, it may be beneficial to
link folate to BSA using a 2000-5000 kDa PEG to increase phototoxic at lower
concentrations while maintaining minimal dark cytotoxicity.

CHAPTER FOUR
EXPRESSION AND FUNCTIONAL CHARACTERIZATION OF THE FOLATE
RECEPTOR DURING ZEBRAFISH EMBRYOGENESIS
Introduction
Folate is a well-studied B vitamin commonly referred to as Vitamin B9. This
vitamin is necessary for cell maintenance and division due to its nature as a methyl donor
required for the synthesis and modification of DNA, RNA, and the amino acids serine
and methionine (Choi and Mason, 2000; Keleman, 2006). Folate deficiency during
human fetal development can lead to neural tube defects (Botez and Reynolds, 1979;
Clarke, et al.., 1998; Reynolds, 2002; Seshadri, 2001). The British Medical Research
Council sponsored research that showed that women who had prior neural tube defect
affected pregnancy reduced the risk of having a subsequent neural tube defect affected
pregnancy by 70% when they supplemented their diets with 4.0 mg per day of folic acid
(Wala and Sheldon, 1991).
Interestingly, folate can be both a cancer protectant and a pro-tumor agent
(Meenan, et al.., 1997; Willet, 1994; Giovannucci, et al., 1993; Farias, et al.., 2015;
Zwicke, et al.., 2012). This discrepancy seems to lie in the balance of the amount of
folate in the system and its bioavailability to cells. During normal cell differentiation in
humans, the ability of each cell to import folate is controlled by the protein Folate
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Receptor 1 (FOLR1). In many tumor cells, the FOLR1 protein is overexpressed,
suggesting a possible target for anti-cancer therapies (Yoo and Park, 2004; Briggs, 2002
The teleost Danio rerio (also known as the common zebrafish) has become a
popular model organism for studying vertebrate development and disease due to its
functionality and the relative ease with which it is possible to subject them to standard
molecular, genetic, and embryological manipulation (Kao, et al.., 2014). As an example,
many of the neural tube defects due to folate deficiency in humans have also been
documented in zebrafish (Blair, et al.., 2005). Approximately 71% of human genes have
at least one zebrafish orthologue, and 47% of these have a direct, one-to-one relationship
with their zebrafish counterpart (Kao, et al.., 2014).
We have defined the expression pattern of zgc:165502, the zebrafish orthologue
of the human FOLR1 gene, during embryogenesis using reverse transcription polymerase
chain reaction (RT-PCR), and whole mount in situ hybridization (WISH). This
expression pattern will allow researchers in multiple fields the ability to study the
endogenous zgc:165502 gene as expressed during embryogenesis.
Methods
Zebrafish care and husbandry. Zebrafish were maintained at Loyola University
Chicago. All studies were performed with the approval of the Institutional Animal Care
and Use Committee (IACUC). Wild-type embryos were raised and staged as described in
Kimmel et al., 1995. Post-gastrulation stages were treated with 0.005% 1-phenyl-2thiourea (PTU) solution to prevent melanin pigment from developing. Embryos older
than 24 h post fertilization (hpf) were treated with fresh PTU solution once a day. Once
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the embryos reached the desired stage, they were dechorionated manually if necessary,
anesthetized with 0.2% Tricaine pH 7.0, then fixed in 4% paraformaldehyde (PFA) in
PBS pH 7.0 at 4°C. After fixing, the embryos were washed four times with phosphate
buffered saline with 0.1% Tween-20 (PBST). After washing, the embryos were placed in
100% methanol (MeOH) and stored at −20 °C.
Reverse-transcription polymerase chain reaction (RT-PCR). RT-PCR was
performed to confirm the presence of the mRNA for the folate receptor at various stages
of early embryo development: 1- to 2-cell, 256-cell, sphere, germ, shield, 1 days post
fertilization (dpf), 2 dpf, 3 dpf, and 4 dpf. The primers were designed to anneal to
sequences in exons on both sides of an intron. Designing the primers in this way allowed
for differentiation between the PCR products that were amplified by any possible
genomic DNA contamination, and those amplified by the cDNA created from the RNA
template. Total RNA was isolated from 50 staged embryos using a TRIzol reagent (Life
Tech) and purified using a Direct-zol kit and its corresponding protocol (Zymo
Research). Of the resulting total RNA, 1.5 µg from each embryo stage was reverse
transcribed using oligo-dT primers (Integrated DNA Technologies) and a SuperScript III
Reverse Transcriptase kit (Life Tech) to generate first-strand cDNA. One microliter of
cDNA from each stage was used as a template for the primers 5’-ATT CCT CAC CTG
AGC AGA ACA TGG-3’ (forward) and 5’-TGA GGT GAG CAC TCA TAG AAG C-3’
(reverse) to amplify a 300 bp fragment of the folate receptor cDNA. The PCR was run
with 35 cycles of 45 s at 95 ˚C, 1 min at the annealing temperature 62 ˚C, and 1 min at 72
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˚C. Ten microliters of the PCR product was analyzed with a molecular weight marker
(Hi Lo ladder, New England BioLabs) on a 1% Tris-acetate-EDTA agarose gel.
In situ hybridization. The complete cDNA sequence of human gene FOLR1 was
used as a query in a BLAST search of the zebrafish reference genome (Zv10). This
yielded a single cDNA clone (7433953) which was obtained as a plasmid clone from
Open Biosystems. The fragment was inserted into pCSdest plasmid 22423 (Addgene)
and linearized using the restriction endonuclease AscI. A digoxigenin-labeled anti-sense
probe was synthesized using a RNA labeling kit with SP6 RNA polymerase (Roche).
The folate receptor sense RNA probe was synthesized and used as a control.
Whole mount in situ hybridization was carried out as presented in Sisson and
Topczewski (2009) and Thisse (2000) using low stringency conditions (50% formamide
hybridization buffer with a .02% Saline-Sodium Citrate Buffer (SSC) final wash).
Embryos were placed in 1.5 mL micro-centrifuge tubes, and rehydrated using serial
dilutions to replace MeOH with PBST (75% MeOH:25% PBST, 50% MeOH:50% PBST,
25% MeOH:75% PBST, 100% PBST). Next, embryos staged between 1 dpf and 4 dpf
were digested using a solution of 1 µL Proteinase K in 2 ml PBST. Embryos that were
staged at 1 dpf were digested for 5 min and embryos staged at 2 dpf and 3 dpf were
digested for 30 min. 4 dpf embryos were digested for 45 min. After digestion the
embryos were placed in 4% PFA for 20 min, and then transferred into PBST. The
embryos were pre-hybridized for 3 h with 500 µL hybridization buffer (Hyb+) that
contained: 50 mL formamide, 25 ml 20X saline-sodium citrate buffer, 5 mg heparin, 50
mg tRNA, 100 µL 0.1% Tween-20, and 460 µL l 0.1M citric acid. During pre-
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hybridization the embryos were kept at 70°C. After 3 h, the embryos were removed from
the incubator, and two embryos from each stage were placed in a single micro-centrifuge
tube for blocking. After this, 300 µl of Hyb+ containing 500 ng of anti-sense probe was
added to each tube (except for the blocking embryos) and kept at 70°C overnight. The
blocking embryos were treated the same as the other samples except they were void of
probe. The following day, the Hyb+ with probe was removed, and each stage was moved
into 0.02% SSC by successive washes of hybridization buffer without tRNA (Hyb-) and
SSC (100% Hyb-, 75% Hyb-:25% 2X SSC, 50% Hyb-:50% 2X SSC, 25% Hyb-:75% 2X
SSC, 100% 2X SSC, 100% 0.02X SSC). Following the SSC washes the embryos were
moved into PBST using serial dilutions. Next all of the embryos except the blocking
embryos were treated with 500 µl blocking solution (20% fetal bovine serum (Life Tech),
2% bovine serum albumin (Sigma) in PBST) for 4 h at room temperature. The blocking
embryos were pre-absorbed with anti-digoxigenin antibody (anti-DIG, Roche) for 4 h.
After 4 h the pre-absorbed antibody was diluted with fresh blocking solution, and used to
replace the blocking solution in each tube. The tubes were placed in the dark overnight at
4 °C. The next day the embryos were washed several times with PBST and freshly made
staining buffer (0.100M Tris-HCl (pH 9.5) (Sigma), 0.100M NaCl (Sigma), 0.1% Tween
20 (Sigma)). Following the washes the embryos were stained with 5-bromo-4-chloro-3'indolyphosphate (BCIP) and nitro-blue tetrazolium (NBT) staining solution (Roche) and
placed in the dark at room temperature. The embryos were monitored closely for staining
and after defined stains developed, the embryos were washed multiple times with stop
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solution (0.5M EDTA in PBST). The resulting embryos were imaged using a Nikon
digital camera fitted to a light stereo microscope using 3.2X magnification.
Synthesis of folate-bovine serum albumin-rhodamine (FA-BSA-RH). FABSA-RH was synthesized as shown in Figure 13. 10 mg of folate (FA) was placed inside
of a small, foil-wrapped Eppendorf tube and dissolved in 200-300 μl of anhydrous
dimethylsulfoxide (DMSO). This solution was then incubated with a 10-fold molar
excess of 1-ethyl-3-(3-dimehtylaminopropyl) carbodimide (EDC) and a 20-fold molar
excess of N-hydroxysuccinimide (NHS) at room temperature for 30 min. The resulting
esterified or “activated” FA was added to a 10-fold molar excess of bovine serum
albumin (BSA) previously dialyzed in bicarbonate buffer at pH 8.0. The mixture was
incubated for 24 h at room temperature and quenched with ethanolamine. The excess FA,
NHS, and ethanolamine was removed by dialyzing overnight in bicarbonate buffer at pH
8.0. Rhodamine B isothiocyanante (RH) was placed inside of a small foil-wrapped
Eppendorf tube dissolved in 200-300 μl of anhydrous DMSO. A 10-fold molar excess of
RH was added to the FA-BSA solution that was previously dialyzed in bicarbonate buffer
at pH 8. The mixture was incubated for 24 h at room temperature and quenched with
ethanolamine. The excess Rhodamine B was removed by dialyzing overnight in PBS at
pH 7.4 in the dark.
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Figure 13. Synthesis Scheme of FA-BSA-RH. Folic acid (1) was reacted with EDC/NHS
to yield “activated” folic acid. Activated folic acid was reacted with lysine residues on
BSA to yield FA-BSA (2). (2) was reacted in buffer with RH (3) to yield the final product
FA-BSA-RH (4).
Uptake of FA-BSA-RH. Wild type zebrafish embryos were collected at 3 dpf.
Three embryos were placed in a single well that contained 3 ml of either embryo media,
BSA in embryo media (50 µM), 50 µM BSA covalently attached to rhodamine (a red
fluorescent dye) (BSA-Rh), or 50 µM BSA covalently attached to rhodamine and folate
(FA-BSA-Rh). The wells were placed in a 37°C incubator overnight in the dark. After 24
h, the solutions were removed and the embryos were washed 3X with embryo media and
returned to the incubator for 24 h. A total of 20 embryos were assayed with each
conjugate (BSA, BSA-Rh, FA-BSA-Rh) and embryo media. Fluorescent images were
taken of each embryo after washes and 24 and 48 h after exposure to the conjugates with
a stereo fluorescent microscope with 3.2X magnification.
Results and Discussion
Conservation of the folate receptor between species. As we are interested in
utilizing zebrafish as a model of FOLR1 protein structure and function, we first set out to
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determine if the zebrafish zgc:165502 protein was similar to its orthologues. To do this,
we obtained sequences for 11 identified or predicted chordate Folr1 proteins spanning
from Ciona intestinalis to Homo sapiens, about 750 million years apart in evolution, to
generate a phylogenic tree (Hedges, et al.., 2015; Shen, et al.., 2012). We also included
the two known human paralogs of FOLR1, FOLR2 and FOLR3, in our comparison as an
out group (Figure 14). Our tree demonstrated that the Folr1 proteins seem to follow the
predicted vertebrate gnathostome phylogenetic order with higher amino acid conservation
being observed within a subclass or clade of animals (see Neopterygii and Mammalia in
Figure 14). Interestingly, the Folr1 amino acid identity conservation is ~50 % for animals
whose last common ancestor existed about 435 million years ago (Shen, et al.., 2012,
Antony, 1996).
The human FOLR1 protein is composed of multiple domains that have been well
characterized for their biological functions (Zhao, et al.., 2011; Lee, et al., 2011). These
domains include an endoplasmic reticulum (ER) signal peptide that is cleaved away after
protein synthesis, a folate receptor family domain (FRF), a glycosyl-phosphatidyl-inositol
(GPI) site, and a transmembrane helices domain (THD, Figure 15). We determined the
percent identity and percent conservation for each of these domains between the human
FOLR1 and other vertebrates, including zebrafish (Figure 15). For this comparison we
used 7 species with published full-length Folr1 proteins.
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Figure 14. Phylogenetic Tree. FOLR1 proteins follows the predicted vertebrate
gnathostome phylogenetic order with higher amino acid conservation being observed
within a subclass or clade of animals.
Of the four domains, the FRF domain had the highest percent identity at 58%.
Interestingly, many of the amino acids that were conserved between human and zebrafish
were also found to be conserved in the other vertebrates looked at, suggesting the
importance of these amino acids. Of particular interest, within the human FOLR1 FRF
domain are two regions that interact with folate: Folate Binding Sites (FBS) 1 and 2. The
human FOLR1 FBS1, amino acids 124-128, consists of WRKER. When compared to
zebrafish, only one amino acid is different (K126 R), which conserves the basic charge
needed at that location. The human FBS2, at amino acids 157-162, consists of
HKGWNW. Again, only one amino acid is different between human and zebrafish
FOLR1 protein in this region. Asparagine 161 has been changed to aspartate acid, both of
which are polar. While this change does result in a negative charge at this location it is

54
interesting to note that five of the nine species looked at have aspartic acid at this location
while the other four have asparagine. Taken together, the high conservation of chordate
Folr1 proteins and the conservation of critical functional domains between zebrafish and
human FOLR1 protein, suggest that the zebrafish Folr1 receptor is a good candidate to
study aspects of vertebrate Folr1 protein function.

Figure 15. FOLR1 Domains. Percent identity and percent conservation for domains
between the human FOLR1 and other vertebrates, including zebrafish .
Zebrafish zgc:165502 is a maternally loaded gene that is present during the
first 4 days of development. To map the expression of the zebrafish folate receptor, we
used reverse transcription-polymerase chain reaction (RT-PCR) on total RNA prepared
from the following zebrafish stages: 1- to 2-cell, 256-cell, sphere, germ, shield, 1 dpf, 2
dpf, 3 dpf, and 4 dpf. Amplification with the designed primers yielded a single band at
the predicted size of 300 bp (Figure 16) for all stages assayed.

55
Expression was seen before the zebrafish maternal-zygotic transition at the 512cell stage (~2.75 h post fertilization), this suggests that zgc:165502 mRNA is maternally
loaded. These findings correlate with previous research demonstrating that multiple genes
in the folate metabolic pathway are also present as early as the 1- to 2-cell stage in (Lee,
et al.., 2012).

Figure 16. RT-PCR Results. zgc:165502 is detected in embryonic stages of zebrafish by
RT-PCR. Each stage assayed presented a single band of 300 bp.
Zebrafish zgc:165502 gene expression during early embryogenesis. An
antisense and sense riboprobe were generated to perform WISH for the stages that
presented a 300 bp band in RT-PCR experiments results, as well as to determine the
spatial temporal expression pattern of the folate receptor of those stages (Figures 17 and
18). All of the stages tested with the antisense probe demonstrated the presence of
zgc:165502 mRNA, while sense probe assayed at the same stages were negative. The
stages from the zygote period (1-cell) up to the late segmentation period (24 hpf) express
the folate receptor globally (Figure 17). After 1dpf the expression pattern of the
zgc:165502 gene becomes more localized and specific (Figure 18). By 2 dpf, the late
pharyngula stage, zgc:165502 expression is seen in the head and heart of the embryo.
Most enzymes in the folate pathway that have been previously investigated in
zebrafish were found to be maternally loaded and expressed throughout the early embryo.
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Inhibition of these enzymes were lethal (Sun, et al.., 2009; Gross and Dowling, 2005;
Kao, et al.., 2007). The results from this investigation support the findings of these
studies, and suggest that during these periods the folate receptor is used to support cell
division although not necessarily cell differentiation.

Figure 17. WISH Results for 1-2 Cell to Shield Stage. zgc:165502 is globally expressed
(a) 1-2 cell (lateral), (b) 256 cell (lateral), (c) sphere (lateral), (d) 30% epiboly (lateral),
(e) germ ring (lateral), (f) germ ring (top), (g) shield (lateral), (h) shield (top)
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Figure 18. WISH Results for 1 dpf to 4 dpf. (a) 1 dpf is globally expressed (b)2 dpf
expression is shown in the head (c) expression is shown in the pectoral and caudal fin (d)
expression is shown in the cloaca and pectoral fin
It has been reported that dihydrofolate reductase (DHFR), an enzyme that plays a
significant role in folate-mediated metabolism, also has a tissue specific expression and is
abundantly expressed in the brains of zebrafish during early development (Sun, et al..,
2011). DHFR knockdown studies resulted in malformation of the heart (Sun, et al..,
2010). Other studies that treat embryos with methotrexate (MTX), a folate antagonist,
showed that rescuing treated embryos with folate resulted in decreasing the cardiac
deformities (Ma, et al.., 2012). Similarly, studies exposing zebrafish to selenite during
early embryo development resulted in cardiac and neural defects, but these effects were
prevented with folate administration (Muralidharon, et al.., 2015). Recently, folic acid
supplementation has been shown to rescue retinal defects induced by ethanol exposure in
zebrafish during retinal neurogenesis (1-2 dpf) (Parkin, et al.., 2009). The results of these
various studies support the conclusion that folate is necessary for cell differentiation.
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Furthermore, if folate is pivotal at these stages of development, the folate receptor will
also be necessary and it should be expressed in corresponding regions, which this study
has shown.
Zebrafish zgc:165502 gene expression during late embryogenesis. Once the
embryo reaches the hatching period (2-3 dpf) and continues to the early larval stage (4
dpf), zgc:165502 expression is seen in specific tissues. The pectoral, dorsal, and caudal
fins, which begin to develop around 36 hpf, start to show zgc:165502 expression by 2
dpf. Both development and expression continue through 4 dpf. The expression of
zgc:165502 mRNA in the fins are consistent with previous studies in literature that
inhibited DHFR. Using low concentrations of MTX, DHFR was inhibited prior to fin
development and the embryo exhibited ventral edemas, dorsal curvature, and a shortened
anterior-posterior axis, along with other defects at this stage (Sun, et al.., 2009). It is
reasonable to infer from this that folate is essential for the growth and development of the
fins.
Development of the digestive tract is initiated around 2 dpf and the gut tube
development concludes around 4 dpf (Pyati, et al.., 2006) when the cloaca begins the
final stages of development (Kalli, et al.., 2008). Expression of the zgc:165502 gene was
detected in the digestive tract at 3 dpf and in the cloaca at 4 dpf. This indicates that the
folate receptor is present at a time and place during development when folate could be
needed to sustain the growth and development of the digestive organs, including the
cloaca.
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Fluorescent-tagged folate is selectively taken up during development. To
further confirm the presence of the zgc:165502 protein 3 dpf embryos were treated with
fluorescent-tagged folate. As a control, embryos were also exposed to the fluorescent
dye, free of folate (RH). After 24 h of exposure, the embryos were washed with embryo
media and observed for fluorescence (Figure 19). Living embryos treated with FA-BSARH demonstrated bright fluorescence in the head and cloaca, which is where we observed
the presence of zgc:165502 mRNA by WISH. All embryos assayed, including controls,
fluoresced in the gut. We hypothesized that this was due to the ingestion of the
fluorescent compounds rather than the zgc:165502 protein being present. To test this
hypothesis, embryos were placed in media free of fluorescent dyes and folate for 24 h
after their initial exposure to fluorescent-tagged folate and then observed again. The
control embryos did not show any residual fluorescence, while the embryos that were
initially treated with fluorescent-tagged folate showed the same fluorescent profile seen
previously. These results demonstrate the ability of tissues shown by in situ hybridization
to have zgc:165502 mRNA also have the ability to internalize folate. We have shown for
the first time, that tagged folate can be selectively taken up during embryo development
in a targeted fashion.

Figure 19. Fluorescent Tagged Folate Uptake. 3dpf staged embryos were treated with 50 µM of fluorescent tagged folate (FABSA-RH) and as a control embryos were also treated with non-folate fluorescent dye at the same concentration. After 24 h
exposure to fluorescent dye (A) and fluorescent tagged folate (B) embryos displayed fluorescence. After an additional 24h in
fluorescent dye (C) and fluorescent folate free media (D), only D exhibited fluorescence.
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Conclusions
The folate receptor provides information as to when (developmentally) and where
(spatially) folate can enter into the zebrafish. This study presents the gene expression
pattern for the zebrafish zgc:165502 gene during embryogenesis. We have shown that the
folate binding sites (FBS) in the FOLR1 protein in humans are conserved in zebrafish. In
addition, we have elucidated the globally expression of the folate receptor mRNA in
zebrafish during the first 24 hpf and the more specific, localized expression during late
embryogenesis.
This information can aid in optimizing current treatments for folate specific
diseases, as well as potentially provide an avenue for researchers to further investigate
folate specific conditions such as neural tube defects.
Many cancers have an upregulated folate receptor (Sudimack and Lee, 2000), and
targeting the receptor has proven to be a useful method to increase specificity and
potency of drug treatments (Leamon and Reddy, 2004). The use of zebrafish and
exploiting the folate receptor can help to advance the field of field of cancer research that
targets the folate receptor. We have demonstrated the ability to exploit the folate receptor
by use of fluorescent tagged folate.

CHAPTER FIVE
SELECTIVE TARGETTING OF CELLS IN ZEBRAFISH USING FOLATE
MEDIATED PHOTODYNAMIC THERAPY AGENT
Introduction
The ability to selectively kill cells in a spatiotemporal fashion can provide insight
into development. Many cancers overexpress the folate receptor (Bisland et al., 1999)
due to its role in the synthesis of nucleic acids and amino acids (Choi and Mason, 2000;
Keleman, 2006). These cells can be selectively targeted by exploitation of the receptor.
Many agents that specifically targets cancerous cells have been developed (Sudiamack
and Lee, 2000; Leamon and Reddy, 2004; Lee and Low, 2012). These agents are taken
up into the cell’s cytoplasm via receptor mediated endocytosis (Sudiamack and Lee,
2000; Leamon and Reddy, 2004; Lee and Low, 2012). When folate (FA) is conjugated to
a photosensitizer (PS), both the FA and the PS can be internalized into the cell (Lee and
Low, 2012). Upon photoactivation the conjugate produces singlet oxygen which damages
the cell and can lead to cell death. This method of effecting specific cells with PS that
produces reactive oxygen species is called photodynamic therapy. Since embryonic cells
also express folate receptors (as shown in Chapter Four) these PDT agents can be used to
investigate early development.
A common PS that has been used in targeted and non-targeted studies is chlorin
e6 (Ce6) agent that has FA and Ce6 covalently attached to bovine serum albumin,
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FA-BSA-Ce6 (discussed in depth in Chapter Three) that is effective as a folate directed
PDT agent in HeLa cell culture.
Selective cell targeting coupled with PDT has been studied in many organism,
and through our search of the literature we believe zebrafish have yet to be used in these
types of studies. Zebrafish are good candidates for these studies because they are
vertebrates and they share a high degree of sequence and functional homology with
humans, their embryos and larvae are transparent making it easy to see the impact of
treatment with invasive techniques, and they produce a large number of offspring at one
time (Kao, et al., 2014).
We have previously elucidated the gene expression pattern for the folate receptor
during zebrafish embryogenesis (discussed in Chapter Four). Here we report on the
exploitation of the receptor by selective targeting of cells that express the folate receptor.
Materials and Methods
Reagents.1-ethyl-3-(3dimethylaminopropyl)carbodimide (EDC), bovine serum
albumin (BSA), anhydrous dimethyl sulfoxide (DMSO), ethanolamine, folate (FA), Nhydroxysuccinimide (NHS), Rhodamine B isothiocyanate (RH), Acridine Orange (AO),
were purchased from Sigma Chemical Company (St. Louis, MO). Chlorin e6 (Ce6) was
purchased from Frontier Scientific (Logan, UT). All other chemicals used were analytical
grade and used without further purification, unless otherwise specified.
Zebrafish care and husbandry. Zebrafish were maintained at Loyola University
Chicago. All studies were performed with the approval of the Institutional Animal Care
and Use Committee (IACUC). Wild-type embryos were raised and staged as described in
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Kimmel et al., 1995. Post-gastrulation stages were treated with 0.005% 1-phenyl-2thiourea (PTU) solution to prevent melanin pigment from developing. Embryos older
than 24 h post fertilization (hpf) were treated with fresh PTU solution once a day. Once
the embryos reached the desired stage, they were dechorionated manually if necessary,
anesthetized with 0.2% Tricaine pH 7.0, then fixed in 4% paraformaldehyde (PFA) in
PBS pH 7.0 at 4°C. After fixing, the embryos were washed four times with phosphate
buffered saline with 0.1% Tween-20 (PBST). After washing, the embryos were placed in
100% methanol (MeOH) and stored at −20 °C.
Synthesis and characterization of non-fluorescent folate targeted compounds.
FA-BSA-Ce6 and BSA-Ce6 were synthesized and characterized as detailed in Chapter
Three. The final products, BSA-Ce6 and FA-BSA-Ce6 were diluted to a final
concentration of 5 µM and 10 µM using embryo media.
Selective cell targeting with FA-BSA-Ce6. Wild type zebrafish embryos were
collected at 2 days post fertilization (dpf) and 3 dpf. Three embryos were placed in a
single well that contained 3 mL of either 5 µM or 10 µM of BSA in embryo media, BSACe6, or FA-BSA-Ce6. The wells were placed in a 37°C incubator overnight in the dark.
After 24 h, the solutions were removed and the live embryos were washed 3X with
embryo media and returned to the incubator overnight. The following day each embryo
was irradiated with light at 660 nm for 1 min, 2 min, 4 min, and 6 min which corresponds
to 5.6, 11.2, 22.5, and 33.7 J/cm2 respectively. Each embryo was determined to be viable
or non-viable based on response to touch and heartbeat. A total of 24 live embryos were
assayed with each conjugate.
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Confirmation of selective cell targeting. After the embryos were treated with
PDT agents as described, they were immersed in 5 μg/ml Acridine Orange (AO) for 10
min. Following treatment with AO each embryo was imaged for less than 60 s using a
stereo fluorescent microscope with FITC filter.
Results
Synthesis of conjugates. We have synthesized FA-BSA-Ce6 and BSA-Ce6 as
previously described in Chapter Three. Briefly, a 10 molar excess of FA that was
previoulsy esterified using a water soluable carbodiimide was covalently attached to BSA
via amidation, producing FA-BSA. BSA-Ce6 was produced in th same manner, except
Ce6 was used in a 20 fold molar excess to BSA. To generate FA-BSA-Ce6, Ce6 was
covalently attached to FA-BSA, by the same esterification and proceeding amidation
reaction. The final conjugates, BSA-Ce6 and FA-BSA-Ce6 were dialyzed in phosphate
buffered saline pH 7.4. Based on UV-Vis absorption spectroscopy it was deteremined
that each sample produced contained 8 covalently attached Ce6 to BSA, and 2 molecules
of FA.
FA-BSA-Ce6 effectiveness in zebrafish. All embryos treated with BSA-Ce6,
BSA, and embryo media that were assayed under all conditions discussed were
determined to be viable for up to 24 h after light exposure. All embryos that were kept in
the dark remained viable for up to 72 h after immersion in conjugates. Embryos exposed
to 1 and 2.5 µM FA-BSA-Ce6 were determined to be viable based on reaction to stimulus
and continued heartbeat for up to 24 h after light exposure.
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The results of FA-BSA-Ce6 at 5 and 10 µM on 4 dpf staged embryos (48 h after 2
dpf embryos were treated with conjugates) are shown in Table 3. Embryos exposed to 1
min and 2 min of light were all deemed viable. The embryos exposed to FA-BSA-Ce6 at
both concentrations were non-viable at the end of 4 min and 6 min light exposure.
Light exposure
5 uM

10 uM

1min

0

0

2 min

0

0

4 min

24

24

6 min

24

24

time

Table 3. Non-viable embryos after PDT treatment. Results of FA-BSA-Ce6 at 5 and 10
µM on 4 dpf staged embryos. Embryos exposed to light greater than 4 min were all nonviable, embryos exposed to light under 4 min were all viable after PDT treatment.
To determine how much light was needed to induce death the trials were video
recorded. Viability was based on heart beat; once the heart beat could no longer be
detected the embryo was deemed non-viable. For 5 µM FA-BSA-Ce6 the embryos were
non-viable on average after 3:42 minu (222 seconds) of continuous light exposure. For 10
µM FA-BSA-Ce6 the heart beat stopped on average after 3:20 minutes (200 seconds) of
continuous light exposure.

67
The results for trials carried out using 5 dpf (48 h after 3 dpf embryos were treated
with conjugates) were also video recorded. Each trial was video recorded from the onset
of light irradiation. For both 5 and 10 µM FA-BSA-Ce6, the embryos were reactive and
visually appeared to be unaffected for light exposure under 3 min. Beginning around 3
min of light irradiation, 5 dpf embryos began to tremor. Of the 36 embryos treated with 5
µM FA-BSA-Ce6, all 36 began to tremor and 12 were unreactive to stimulus (did not
move when touched). 36 embryos were treated with 10 µM FA-BSA-Ce6 and all began
to tremor beginning at 3 min of light irradiation and were unreactive to stimulus, unlike
the 5 µM samples. All embryos regained “normal” functions (based on heart beat,
reaction to touch, phenotype) after 24 h of irradiation.
Selective targeting of cells. To visualize cells that were effected by
photodynamic therapy treatment with 5 and 10 µM FA-BSA-Ce6 we carried out cell
death assay with acridine orange. The results of trials with 10 µM FA-BSA-Ce6 are
presented in Figure 19. As a control we treated embryos staged at 5 dpf in embryo
media. 5 & 10 µM FA-BSA-Ce6 embryos show significant cell death over control. There
appears to be no significant difference between 5 & 10 µM FA-BSA-Ce6. 36 embryos
were assayed, 4 died while determining correct acridine orange concentration. The other
32 exhibited the same fluorescence pattern.
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Figure 20. Acridine Orange Assay Results. 5 dpf Embryos treated with FA-BSA-Ce6
showed significant cell death over embryo media control. There was no observable
difference between 5 and 10 µM samples. Image presented is indicative of both
concentrations.
Conclusions
Leamon and colleagues (Leamon, et. al, 1993) and many others have shown that
the folate receptor in cell culture can be exploited with folate conjugated
macromolecules. We hypothesized that by attaching FA to our BSA-Ce6 carrier
molecule, the conjugate will be taken up by receptor mediated endocytosis. Previous
work in our laboratory has proven that not only does zebrafish express the folate receptor
during embryogenesis (shown in Chapter Four), but they can also take up a FA bound to
a macromolecule via receptor mediated endocytosis (Chapter Four). In this study we
synthesized an analog of the fluorescent compound produced in prior studies presented in
Chapter Three. We replaced the fluorescent dye with a photoactive dye, Ce6. Ce6 is
known for its large quantum yield of singlet oxygen produced via photodynamic action.
In this study we set out to exploit the folate receptor in zebrafish to selectively target and
effect cells that express the folate receptor.
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Photodynamic treatment trials were carried out on zebrafish embryos. To ensure
that the results produced by the light trials were due to the photodynamic action of the
targeted compounds we carried out these trials in the dark. All embryos exposed to FABSA-Ce6, BSA-Ce6, BSA, and embryo media were viable up to 48 h after exposure. The
same cannot be said for embryos treated FA-BSA-Ce6 that were irradiated with light.
From this we can conclude that the results we received from light based studies were due
to phototoxicity of the conjugates. These results support the results presented in Chapter
Three, where over 96% of HeLa cells survived after being exposed to the conjugates in
the dark, yet there was significant cell death upon photoactivation.
Photodynamic treatment of 4 and 5 dpf with our targeted agents resulted in all
embryos treated with lower concentrations, 1 and 2.5 µM FA-BSA-Ce6, and BSA-Ce6,
remained viable after treatment with up to 6 min of light. In addition, all embryos that
were exposed to controls survived as well as embryos exposed to the conjugates but not
irradiated with light survived. This was to be expected, because based on our results from
the cell culture trials, where 26% of cells were non-viable after treatment with 2 µM FABSA-Ce6, and less than 2% of cells were non-viable for cells kept in the dark. Therefore,
we concluded that our conjugates are not cytotoxic in the dark, and 1 and 2.5 µM FABSA-Ce6 combined with 6 min of light does not produce significant cell death.
All embryos survived light treatment with 5 and 10 µM BSA-Ce6 and BSA. 4 and
5 dpf embryos that were treated with 5 and 10 µM FA-BSA-Ce6 survived treatment with
1 and 2 min of light. 4 dpf embryo treated at this same concentration but higher light
dosage, 4 and 6 min, did not survive, yet, 5 dpf embryos treated at these same
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concentrations remained viable, but treatment induce tremors after 3 min of light
exposure. The embryos were checked 24 h after the induction of tremors and all signs of
this effect were absent. To further investigate, those same embryos were exposed to light
again. This second exposure did not induce tremors or any other noticeable effects. When
checked for cell death, these embryos exhibited enhanced cell death over controls. Based
on these results we concluded that our targeted PDT agent effects specific cells, not all
cells.
Discussion
Folate is a B vitamin that plays a significant role in the prevention of neural tube
defects (NTDs) and homocysteinemia (Barnabe, et al., 2015; Williams, et. al, 2015;
Mills, et al., 1995; Rosenquist, et al., 1996). NTDs are malformations of the brain and
spinal cord that occurs during gestation (Botto, et al., 1999; Lemuire, 1988). Folate is
needed for the methylation of homocysteine to form methionine and the synthesis of
deoxynucleotides needed for DNA replication (Kang, et al., 1987; Krishnaswamy and
Nair, 2001). Increased levels of homocysteine (homocysteinemia) are suspected to play
important roles in developmental defects and is a risk factor for ischemic heart disease
(Krishnaswamy and Nair, 2001; Wald, et al., 1998). NTDs and the effects of
homocysteine have been documented in zebrafish (Blair, et al., 2005; Muralidharon, et
al., 2015; Parkin, et al., 2006). These studies show that inhibition of enzymes that
metabolize folate increased the occurrence of these conditions, and supplementation with
folate decreased their occurrence.
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This study shows that cells that express the folate receptor can be selectively
targeted and manipulated over cells that do not express the receptor. Photodynamic
treatment with 5 dpf resulted in the embryo remaining viable, yet tremors were induced.
The results from the acridine orange assay demonstrates that we effected selected cells.
This discovery can lead to further investigation of folate specific diseases and cancers, in
addition to helping to understand embryonic development.

CHAPTER SIX
CONCLUSIONS
Photodynamic therapy (PDT) utilizes oxidative damage to kill cancerous cells.
Light excites a photosensitizer (PS), which then reacts with oxygen to form a highly
reactive oxygen species, which includes singlet oxygen. This singlet oxygen reacts with
cellular macromolecules to cause lethal damage. A prevalent concern with current FDAapproved PDT drugs is that they exhibit low selectively for cancerous cells over healthy
cells. An approach to enhance selectively is to covalently attach a targeting moiety to a
PS. Many cancers overexpress the folate receptor (Zwicke 2012; Parker 2005), therefore
generating an agent that selectively targets that receptor is beneficial. The main objective
of this research was to synthesize and characterize the folate directed, protein based
photodynamic therapy agent, FA-BSA-Ce6. In addition, we wanted to show its
effectiveness as a selective cell targeting agent in cell culture and in vivo.
The PS used in our conjugate was chlorin e6 (Ce6). Ce6 is a useful PS due to its
absorbance in the optimum therapeutic window and high quantum yield of singlet
oxygen. In addition, Ce6 has three carboxyl groups that provides sites for straightforward
conjugation to other molecules that contain primary amines. A major drawback to Ce6 is
its tendency to aggregate in aqueous environments. To overcome this disadvantage, we
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conjugated Ce6 to the protein, bovine serum albumin (BSA) through an amidation
reaction with the lysine residues on BSA.
BSA served as a scaffold to which multiple molecules of Ce6 could be attached
due to its high number of lysine residues. Although BSA has 60 lysine residues, Huang
and Kim showed that only 34 of those residues could be modified via lysine specific
crosslinkers and those lysines were between 20-24 Å apart. We hypothesize that due to
steric hindrance we were able to attached 10 molecules of Ce6 and two molecules of FA
onto one molecule of BSA despite using ratios of Ce6:BSA as high as 30:1 and FA:BSA
as high as 10:1.
An effective PDT agent will be phototoxic upon irradiation with light at the
appropriate wavelength, but not cytotoxic in the absence of light. By using the singlet
oxygen sensor, ρ-nitroso-N,N’-dimethylaniline (RNO), we were able to confirm that
singlet oxygen was produced upon photoactivation of FA-BSA-Ce6 with 660 nm light
and that singlet oxygen was not produce in the absence of light in vitro. In HeLa cell
culture, cells that were exposed to FA-BSA-Ce6 varying in concentration from 1-10 µM
that were kept in the dark resulted in 93% or greater cell survival. Cell survival decreased
significantly, to as low as 5% upon photoactivation. In vivo studies with zebrafish
embryos that were exposed to 5 and 10 µM FA-BSA-Ce6 but kept in the dark resulted in
all embryos remaining viable for at least 48 h after exposure and none of the embryos
remained viable after photoactivation with light times greater than 3 mins. Results from
these in vitro and in vivo studies showed that FA-BSA-Ce6 is not cytotoxic in dark but it
is phototoxic upon irradiation at 660 nm.
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As shown in Figure 12 HeLa cell survival is both concentration and light dose
dependent. As the concentration of FA-BSA-Ce6 increase and as light exposure time
increases (thus irradiation energy increases), cell survival decreases. The same effects are
not seen with BSA-Ce6 (Figure 11). In fact, cell survival across all light irradiation times
remained above 92% for BSA-Ce6. In zebrafish trials, the trend continued. Embryos
exposed to BSA-Ce6 remained viable upon photoactivation. We synthesized a fluorescent
analog of FA-BSA-Ce6 that contained FA-BSA, but Ce6 was replaced with Rhodamine B
(RH), due to Ce6 poor fluorescence. Zebrafish embryos were treated with BSA-RH or FABSA-RH. After allowing time for the embryo’s gut to empty, embryos treated with BSARH showed little to no fluorescence. Embryos treated with the FA-BSA-RH brightly
fluoresced. Additionally, the gene expression pattern for the folate receptor during
zerbrafish early development was elucidated. Embryos treated with FA-BSA-RH exhibited
fluorescence in the same pattern that was shown via whole mount in situ hybridization
(WISH). From the fluorescence data using FA-BSA-RH, the WISH data, the high cell
survival after treatment with BSA-Ce6 and light, and the low cell survival from treatment
with FA-BSA-Ce6 under the same conditions, it is highly suggestible that the conjugate is
folate directed, and possibly being taken up via receptor mediated endocytosis.
Photodynamic treatment using FA-BSA-Ce6 with embryos staged at 5 days post
fertilization (dpf), induced tremoring, although the embryos remained viable. Acridine
orange experiments showed that cell death was occurring after treatment, and many of
those cells exhibited florescence with treatment with FA-BSA-RH, and those cells showed
the presence of the folate receptor in WISH experiments. This shows that FA-BSA-Ce6
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can selectively target cells that express the folate receptor. The synthesis of FA-BSA-Ce6
coupled with being able to selectively target and effect folate dependent cells in zebrafish
opens up many new opportunities for investigation. Zebrafish share a high homology
similarity to humans therefore they are good candidates as in vivo models to look into folate
specific diseases as well as cancers. The folate targeted PDT agent could also be used to
aid in understanding embryonic development. Research has shown that folate may play a
role in alzheimer’s disease, nueral tube defects, cancers, cardiac diseases, and other
neurological conditions (Botez and Reynolds, 1979; Clarke, et al. 1998; Reynolds, 2002;
Seshadri, 2001). By using a folate directed agent, these diseases can be further examined
and understood.
Besides knowing that FA-BSA-Ce6 produces singlet oxygen and singlet oxygen is
toxic to cells, the actual mode or pathway to cell death is not well understood. It is not clear
at what point during irradiation is singlet oxygen being produce. The studies discussed in
this dissertation were end point analysis studies. It would be beneficial for studies to be
carried out that monitor the production of singlet oxygen. This can be accomplished by in
assay ROS detectors.
Depending on the stage of zebrafish embryo, results from photodynamic treatment
varied. Younger staged embryos died, while older staged embryos survived but began to
tremor. Studies that look into what particular cells are being effected in vivo can provide
deeper insight. Investigations into an optimum conjugate exposure time, along with
elucidating the cascading events that occur after treatment with FA-BSA-Ce6 can and
should be further explored in both cell culture and in vivo. Those studies will provide
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insight into how the cell responds to the treatment prior to cell death and can lead to more
efficient and optimized conjugates.
FA-BSA-Ce6 provided cell death in both HeLa cell culture and in zebrafish
embryos. Available molecular oxygen is a big contributor to the effectiveness of PDT.
Cancer tumors tend to be hypoxic. Therefore, if a PDT agent is able to not only selectively
target the cancerous cell, but also bring with it molecular oxygen, the effects of the PDT
agent can be increased. Research in our laboratory has shown that a nanoparticle of up to
8 modified hemoglobin molecules can be synthesized, and this nanoparticle has a high
affinity for oxygen (Webster, 2016 in press). Therefore, synthesizing an analog of FABSA-Ce6, by replacing BSA with the modified hemoglobin, can potentially deliver up to
10 molecules of Ce6, along with 8 molecules of hemoglobin can be beneficial. Each
molecule of hemoglobin will potentially carry a molecule of oxygen inside the tumor,
thereby increasing the availability of molecular oxygen, thus increasing the generation of
singlet oxygen.
FA-BSA-RH was able to selectively target cells that express the folate receptor.
Therefore, this analog can potentially be used for tumor imaging before and/or after
treatment. Many cancers are treated from multiple approaches. Being able to have the
tumor fluoresce can optimize surgical removal of tumors. In addition, provide a way to
visualize how much of the tumor remains after surgery or after other cancer related
treatments.

APPENDIX A
HEMOGLOBIN BASED PDT AGENTS
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PDT potency has a direct relationship with oxygen availability. Cancerous cells
are typically hypoxic due to the aggregation of cells, which prevents an appropriate
vascular system from being developed. Hence, the more oxygen available to the
photosensitizer the more cellular damage can be done. Crosslinked hemoglobin (XLHb)
has been shown to have an increased oxygen affinity. Therefore, conjugating Ce6 to
XLHb should allow for more molecular oxygen to be present inside the targeted cells,
and result in increased cellular death.
We successfully synthesized 60 µM XLHb, FA-XLHb, and FA-XLHb-Ce6. The
conjugates were extracted using cold acid/acetone mixture to quantify the amount of folates
and chlorin e6 molecules covalently bound to the protein as described in Chapter Three.
Under these harsh conditions, the heme dissociates from the globin, and the globin
precipitates along with any covalently bound molecules. FA-XLHb-Ce6 proved to have
approximately 2.67 folates and 3 chlorin e6 molecules bound per protein molecule (Table
4).
Trials

# of FA

# of Ce6

.

1

3

3

2

2

3

3

3

3

Table 4. Acid/Acetone Extraction. Average of 2.67 folates, and 3 chlorin e6 molecules
bounds per XLHb molecule
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A key component to successful PDT is providing sufficient oxygen that can be
converted into singlet oxygen. The FA-XLHb-Ce6 conjugate was assayed for its oxygen
affinity. An oxygen binding curve was collected (Figure 21) and a Hill plot was constructed
to determine the conjugate’s p50 (Figure 22). The p50 is the pO2 at which the hemoglobin
becomes 50% saturated with oxygen. As the p50 decreases, oxygen affinity increases.
Unmodified hemoglobin has a p50 of approximately 26.5 mmHg. The p50 for the
crosslinked hemoglobin that was used to synthesize FA-XLHb-Ce6 was determined to be
10.72 mmHg (+/- .245). The p50 for FA-XLHb-Ce6 was determined to be 7.98 mmHg (+/.215) (Figure 21 and Table 5).
From Hill plots a Hill coefficient, “n”, can be calculated. The Hill coefficient is a
measure of cooperativity. Cooperativity is a measure of affinity for a ligand, and in our
case an oxygen molecule, to bind to a substrate (crosslinked hemoglobin) upon the binding
of another ligand at a different binding site. A Hill coefficient that is greater than one
denotes positive cooperativity. The Hill coefficient for XLHb was determined to be 1.03
(+/- .010) and for FA-XLHb-Ce6 it was determined to be 1.70 (+/- .682) (Table 5 and
Figure 22). This data demonstrates that upon conjugating XLHb to folate and chlorin e6 its
oxygen affinity was enhanced. These results indicated that FA-XLHb-Ce6 oxygen affinity
is greater than myoglobin (2.5 mmHg), yet lesser than Hb. Therefore, FA-XLHb-Ce6
should be able to hold on to oxygen in normoxic conditions, and deliver its oxygen in
hypoxic conditions, such as in cancerous tumors.
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Sample

P50

n

XLHb

10.72 (+/- .245)

1.03 (+/- .010)

FA-XLHb-Ce6

7.98 (+/- .215)

1.70 (+/- .682)

Table 5. P50 and Hill Coefficients. Data table of calculated p50 and hill coefficient for
XLHb abd FA-XLHb-Ce6
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Figure 21. Oxygen Binding Curves for FA-XLHb-Ce6.
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Hill Plots
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Figure 22. Hill Plots Calculated from Oxygen Binding Curves
Each conjugate was subsequently assayed for phototoxicity and dark cytotoxicity
in HeLa cell culture using a 96 well plate and Cell Titer Blue Assay as previously
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Figure 23. XLHb Based Conjugates Cell Culture Results.
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The crosslinked hemoglobin compounds were shown to be cytotoxic. Crosslinked
hemoglobin provided 118.22% cell survival, while the XLHb-Ce6 and FA-XLHb-Ce6
provided 63.57% and 50.69% cell survival, respectively. Phototoxicity results were
81.13%, 18.52%, and 58.32% for XLHb, XLHb-Ce6, FA-XL-Ce6 respectively (Figure
23). These results do not support our hypotheses. After further examination of the
hemoglobin based conjugates, we determined that the hemoglobin had oxidized to
become methemoglobin. Methemoglobin contains Fe3+. This oxidized form of
hemoglobin has a lower capacity to bind oxygen in comparison to unoxidized
hemoglobin. Conversely, Fe3+ has a higher affinity for bound oxygen. When oxygen
binds to methemoglobin the remaining Fe2+ of the tetramer have an increased affinity of
oxygen. This results in the methemoglobin poorly delivering oxygen to tissues, causing
hypoxia, which is lethal to cells. The samples were placed onto a dithionite reduction
column, and results were not improved. The conjugates were successfully reduced, but
after 24 h of incubation in a humidified atmosphere we hypothesize that the conjugates
returned to the met-form.
The results obtained using a significant lesser amount of conjugates (10 µM) of
BSA based conjugates provided more consistent (based on standard deviations) data and
proved to be a more effective conjugate. It should be noted that the amount of light
energy used was in these XLHb studies was 81 mJ/cm2/nm while the BSA studies were
carried out with 168 J/cm2/nm.
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Brief Methods
Synthesis of XLHb. Prior to crosslinking hemoglobin at the β82-Lys residues,
HbA was dialyzed in MOPS buffer at pH 7.0. The HbA was then reacted with bis-(3,5
dibromosalicyl) fumarate (DBSF) at a 1:1.1 molar ratio. Subsequently, it was incubated
for 2h at 37 °C. The reaction was terminated on ice and reaction mixutre was dialyzed in
.01 M Tris buffer at pH 8.5 overnight. The crosslinked hemoglobin was separated from
umodified hemoglobin using a Sephadex A-50 column with a pH gradient of 8.5-7.0.
XLHb was confirmed by SDS PAGE-gel electrophroesis.
Synthesis of FA-XLHb. Folic acid was placed inside of a small eppendorf tube
covered with foil and dissolved in 200-300μl of dry DMSO. Next, it was incubated with a
10 fold molar excess of 1-ethyl-3-(3-dimehtylaminopropyl) carbodimide(EDC) and a 20
fold molar excess of N-hydroxysuccinimide (NHS) at room temperature for 30min. A 10
fold molar excess of the esterified “acitivated” folic acid per XLHb tetramer was added to
the XLHb solution that was previously dialyzed in bicarbonate buffer at pH 8.0 The
mixture was incubated for 24h at room temperature and quenched with ethanolamine.
The excess folic acid, NHS and ethanolamine was removed by dialyzing overnight in
PBS at pH 7.4.If the FA-XLHb were to be added to chlorin e6 it was dialyzed in
bicarbonate buffer at pH 8.0.
Synthesis of XLHb-Ce6. Chlorin e6 was placed inside of a small eppendorf tube
and covered with foil and dissolved in 200-300μl of dry DMSO. Next, it was incubated
with a 10 fold molar excess of 1-ethyl-3-(3-dimehtylaminopropyl) carbodimide(EDC)
and a 20 fold molar excess of N-hydroxysuccinimide at room temperature for 30min. A
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10 fold molar excess of the esterified “acitivated” chlorin e6 per XLHb tetramer was
added to XLHb that was previously dialyzed in bicarbonate buffer at pH 8.0 The mixture
was incubated for 24h at room temperature and quenched with ethanolamine. The excess
chlorin e6, NHS and ethanolamine was removed by dialyzing overnight in PBS at pH 7.4.
Synthesis of FA-XLHb-Ce6. Chlorin e6 was placed inside of a small eppendorf
tube and covered with foil and dissolved in 200-300μl of dry DMSO. Next, it was
incubated with a 10 fold molar excess of 1-ethyl-3-(3-dimehtylaminopropyl) carbodimide
(EDC) and a 20 fold molar excess of N-hydroxysuccinimide (NHS) at room temperature
for 30min. A 10 fold molar excess of the esterified “acitivated” chlorin e6 per XLHb
tetramer was added to the FA-XLHb solution that was previously dialyzed in bicarbonate
buffer at pH 8.0 The mixture was incubated for 24h at room temperature and quenched
with ethanolamine. The excess chlorin e6, NHS and ethanolamine was removed by
dialyzing overnight in PBS at ph 7.4.
Oxygen binding. Four milliliters XLHb or FA-XLHb-Ce6 in MOPS buffer pH
7.0 was placed inside of the Hemox Analayzer Model B. The sample was allowed to
equilibrate until it has reached 37°C (approximately 30min). The XLHb is oxygenated
with air supplied from an air tank. After the XLHb has been completely oxygenated and
the pO2 has been adjusted to 150mmHg, the sample is deoxygenated by switching off the
air and turning on the nitrogen. The completion of the curve is reached when the pO2
approaches zero.

APPENDIX B
PEG BASED PDT AGENTS
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A PEG based conjugate was synthesized in addition to the protein based
conjugates. The amines on the PEG allowed for the same carbodiimide esterification
chemistry to be used for conjugation of folate and dye that was used with the protein
based conjugates. It also helped maintain solubility. The 4 arm-amine PEG
(CreativePEGworks, Winston Salem, NC 27113) (Figure 24), was placed inside of a vial
covered with foil. A fifty fold molar excess of chlorin e6, 50 fold molar excess of 1hydroxybenzotriazole, 17 fold molar excess of folic acid, 50 fold molar excess of EDC
was added to the vial and they were dissolved with 3-5mL of dry DMF. Once all reagents
were dissolved a 50 fold molar excess of triethylamine was addition to the mixture and
the vial was placed on a stir plate at 4°C. The resulting mixture was separated using gel
filtration, and the number of molecules bound was determined via UV-Vis
spectrophotometry for each fraction collected. Chlorin e6 has maxima absorption at 660
nm, and folate has maxima absorption at 363 nm. The absorbances at 363 nm was
corrected for slight overlapping absorption of chlorin e6 and the ratio of dye to folate was
calculated (Table 6). It was determined that fraction two contained the desired the ratio,
3:1, and was subsequently used in two HeLa Cell Culture trials. The results of the two
trials indicated that the 19% and 48% of cells survived respectively after irradiation with
light. In the dark the conjugates showed 54% cell survival. Therefore, the conjugate was
deemed cytotoxic. It should be noted that the unlike the protein based conjugates cell
survival was assayed using MTT and not Cell Titer Blue.
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Figure 24. 4-Arm Amine PEG.

Fraction

Ratio (Ce6:FA)

1

7.88

2

3.09

3

3.89

4

3.36

5

2.56

6

4.28

7

4.74

8

3.96

Table 6. Ratio of Ce6:FA Bound to 4-Arm Amine PEG. Fraction separated and collected
via gel filtration using a G-10 Sephadex column. An UV-vis spectrum was taken of each
fraction and subsequently ratios were determined

APPENDIX C
LAMP STUDIES
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To determine the exact energy output of the lamp, its energy was measured
against a calibrated light source. These experiments were carried out with the assistance
of Dr. Robert Polak in the Physics Department at Loyola University Chicago. The
experiment was briefly explained by Dr. Polak in an email sent to RoJenia Jones on
August 12, 2014. The text from the email is below:
“The total power emitted in electromagnetic waves for a light source is called the radiant
flux and is measured in units of Watts (W). The power emitted by the light source for an
electromagnetic wave at a specific wavelength is called spectral radiant flux and is
typically measured in (W/nm).
To determine the spectral radiant flux of an object, we compare the light being emitted by
it at a specific wavelength to that being generated by a calibrated light source. In this
case, we have a calibrated light from Labsphere, which consists of a 2π (“two-pi”)
incandescent light source being driven by a calibrated power supply. This light enters an
integrating sphere and the detector used is an opal glass. By comparing the light energy
on the detector to that of an unknown source at a specific wavelength, we can then
determine the spectral radiant flux of the unknown source.
The opal glass itself is not a detector though. Instead we use a Topcon SR-3
Photoradiometer to determine the spectral radiance (light energy per unit area per unit
solid angle) on the surface of the opal glass. The spectral radiant flux of the unknown
source can then be determined by:
the spectral radiant flux of the unknown source, is the spectral radiant flux of the
calibrated light source (data provided by Labview), is the spectral radiance of the opal
glass with the unknown source and is the spectral radiance of the opal glass with the
calibrated light source.
In this case, we actually aren’t interested in the spectral radiant flux of the unknown light
source, but the light power per unit area per unit wavelength where the cultures are
placed. This is the spectral irradiance and is simply the spectral radiant flux of the light
entering the integrating sphere through an open port divided by the area of that port.
To determine this, the light source was placed 3 inches from the port opening and moved
to measure the light entering the sphere that would correspond to different positions of
the culture. We broke this into 12 different bins (each representing a different area of the
culture tray). Using the above formula to determine the spectral radiant flux incident
upon each bin, we can then determine the spectral irradiance by dividing this result by the
area of the port opening”
All measurements were taken with the source 16 inches from the tray. The
irradiance will go as 1/r2 from the source, so changing the distance from 16 inches to 18
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inches will result in a 21% decrease in the irradiance. There were three trials completed
for each lamp source tested. Below is a diagram of each “bin”:

1

2
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4

5

6

7

8

9

10

11

12

Figure 25. Lamp Bins
All data reported in this dissertation (unless otherwise stated) was carried out with a 120
red LED lamp (660 nm) purchased from Elixa (http://www.elixa.com/shop/120-led-red660nm/). The LED array is approximately 3/4″x 2″x 4″. The results from the light
intensity study for wavelengths 380 – 780 nm is presented in Figure 26.
In Table 7 and Figure 27, the data is presented for the amount of energy produced at 660
nm with the lamp 3 inches away from the test surface for 1-10 min.
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Figure 26. Lamp Intensity

MINUTES
1
2
3
4
5
6
7
8
9
10

J/CM2/NM
5.619322266
11.23864453
16.8579668
22.47728906
28.09661133
33.7159336
39.33525586
44.95457813
50.5739004
56.19322266

Table 7. Energy Output at 660 nm for 1-10 minutes
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